Publications: Prof David Baker

Allen-Philbey K, Stephenson S, Doody G, MacDougall A, Aboulwafaali M, Ammoscato F, Andrews M, Gnanapavan S et al. ( 2024 ) . Effects of cladribine on intrathecal and peripheral B and plasma cells . Clinical & Experimental Immunology

Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D et al. ( 2024 ) . Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells . Clinical Immunology vol. 269 ,

Pingitore V, Pancholi J, Hornsby TW, Warne J, Pryce G, McCormick LJ, Hill J, Bhosale G et al. ( 2024 ) . Delocalized quinolinium-macrocyclic peptides, an atypical chemotype for CNS penetration . Science Advances vol. 10 , ( 28 )

Thomson A, Horne R, Chapman C, Bharadia T, Burke P, Colwell E, Harrington M, Boskovic B et al. ( 2024 ) . Engaging a community to focus on upper limb function in people with multiple sclerosis: the ThinkHand campaign case study . Research Involvement and Engagement vol. 10 , ( 1 )

Mistry N, Hobart J, Rog D, Muhlert N, Mathews J, Baker D, Giovannoni G ( 2024 ) . Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis . Multiple Sclerosis and Related Disorders vol. 88 ,

Ammoscato F, Skonieczna J, Bestwick J, Holden D, Aboulwafa M, Andrews M, Turner B, Marta M et al. ( 2024 ) . Prospective Longitudinal Study of Cladribine Tablets (CLADB Study) Demonstrates Sustained Reduction in Kappa Free Light Chains in Relapsing Multiple Sclerosis (RRMS) at 96 Weeks (P10-6.008) . Neurology vol. 102 , ( 17_supplement_1 )

Zhang JZ, Nguyen WH, Greenwood N, Rose JC, Ong S-E, Maly DJ, Baker D ( 2024 ) . Computationally designed sensors detect endogenous Ras activity and signaling effectors at subcellular resolution . Nature Biotechnology vol. 42 , ( 12 ) 1888 - 1898 .

Baker D, Church G ( 2024 ) . Protein design meets biosecurity . Science vol. 383 , ( 6681 ) 349 - 349 .

Neunie OAM, Rabbani W, Baker D, Chambers ES, Pfeffer PE, Kang AS ( 2024 ) . Immunogenicity of biologics used in the treatment of asthma . Human Antibodies vol. 32 , ( 3 ) 121 - 128 .

Baker D, Kang AS, Giovannoni G, Schmierer K ( 2023 ) . Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 82 ,

Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S et al. ( 2023 ) . Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis . Therapeutic Advances in Neurological Disorders vol. 16 ,

Baker D ( 2023 ) . Proteomic interrogation of the meninges reveals the molecular identities of structural components and regional distinctions along the CNS axis . Fluids and Barriers of the CNS

Dubuisson N, de Maere d'Aertrijcke O, Marta M, Gnanapavan S, Turner B, Baker D, Schmierer K, Giovannoni G et al. ( 2023 ) . Anaesthetic management of people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 80 ,

Seaton A, Baker D, Hedstrom AK, Alfredsson L, Schmierer K ( 2023 ) . Organic solvents and Multiple Sclerosis: the doubled risk dilemma . Occupational Medicine vol. 73 , ( 6 ) 300 - 303 .

Dobson R ( 2023 ) . Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination . Multiple Sclerosis Journal

Baker D ( 2023 ) . Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels . Pharmaceuticals vol. 16 , 972 - 972 .

van Noort JM, Baker D, Kipp M, Amor S ( 2023 ) . The pathogenesis of multiple sclerosis: a series of unfortunate events . Clinical & Experimental Immunology vol. 214 , ( 1 ) 1 - 17 .

Baker D, Forte E, Pryce G, Kang AS, James LK, Giovannoni G, Schmierer K ( 2022 ) . The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination . Multiple Sclerosis and Related Disorders vol. 69 ,

Baker D, Vainchtein ID ( 2022 ) . Characterizing microglial gene expression in a model of secondary progressive MS . Glia

Licht‐Mayer S, Campbell GR, Mehta AR, McGill K, Symonds A, Al‐Azki S, Pryce G, Zandee S et al. ( 2022 ) . Axonal response of mitochondria to demyelination and complex IV activity within demyelinated axons in experimental models of multiple sclerosis . Neuropathology and Applied Neurobiology vol. 49 , ( 1 )

Schmierer K, Redha I, Hammond V, Baker D, Barkhof F, Hooper R, Rashid W, Singh-Curry V et al. ( 2022 ) . 152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,

Schmierer K, Baker D, Nawaz T, Allen-Philbey K, Barkhof F, Chataway J, Hooper R, Mihaylova B et al. ( 2022 ) . 153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS) . Journal of Neurology Neurosurgery & Psychiatry . vol. 93 ,

K A-P, A S, T B, AC J, A M, S G, R D, G G et al. ( 2022 ) . Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 65 ,

Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R, Evangelou N et al. ( 2022 ) . Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 64 ,

Baker D, MacDougall A, Kang AS, Schmierer K, Giovannoni G, Dobson R ( 2022 ) . Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals? . Clin Exp Immunol vol. 207 , ( 3 ) 263 - 271 .

Nutma E, Fancy N, Weinert M, Marzin MC, Tsartsalis S, Muirhead RCJ, Falk I, de Bruin J et al. ( 2022 ) . Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases .

Allen-Philbey K, Marta M, Gnanapavan S, Baker D, Schmierer K ( 2022 ) . Disease activity after cladribine immune reconstitution therapy: To repeat or to retreat? (P9-4.002) . Neurology vol. 98 , ( 18_supplement )

Guo L, Luong V, Gregson A, Baker D, Selwood D, Cordeiro MF ( 2022 ) . VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma . Acta Ophthalmologica vol. 100 , ( S267 )

Ichimura Y, Baker D ( 2022 ) . Acute Inhalational Injury . Encyclopedia of Respiratory Medicine , Elsevier

Allen-Philbey K, Andrews M, Redha I, Papachatzaki M, Marta M, Gnanapavan S, Mathews J, Turner B et al. ( 2022 ) . CLADRIPLAS: Does cladribine Target CNS plasma cells and reduce neuro-axonal damage in people with MS? . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 769 - 770 .

Vickaryous N, Rios F, Schalk L, Asardag AN, George K, Kang A, Baker D, Giovannoni G et al. ( 2022 ) . COVID-19 humoral and T-cell mediated vaccination responses in people with multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 680 - 680 .

Upcott M, Tallantyre EC, Scurr MJ, Vickaryous N, Richards A, Anderson V, Baker D, Chance R et al. ( 2022 ) . Humoral and T- cell response to multiple COVID-19 booster vaccinations in people with MS . MULTIPLE SCLEROSIS JOURNAL . vol. 28 , 365 - 366 .

Baker D ( 2021 ) . CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis . Multiple Sclerosis and Related Disorders

Allen-Philbey K, De Trane S, Mao Z, Álvarez-González C, Mathews J, MacDougall A, Stennett A, Zhou X et al. ( 2021 ) . Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients . Therapeutic Advances in Neurological Disorders vol. 14 ,

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study . Multiple Sclerosis and Related Disorders vol. 57 ,

Rupnik M, Baker D, Selwood DL ( 2021 ) . Oligodendrocytes, BK channels and the preservation of myelin . F1000Research vol. 10 ,

Dobson R, Baker D, Kang A, Schmierer K, Giovannoni G ( 2021 ) . COVID-19 vaccine response in people with multiple sclerosis . Annals of Neurology

Marta M, Baker D, Creeke P, Pryce G, Gnanapavan S, Giovannoni G ( 2021 ) . Antigen-specific tolerization in human autoimmunity: Inhibition of interferon-beta1a anti-drug antibodies in multiple sclerosis: A case report . Multiple Sclerosis and Related Disorders vol. 56 ,

Rupnik M, Baker D, Selwood DL ( 2021 ) . Oligodendrocytes, BK channels and remyelination . F1000Research vol. 10 ,

Baker D, Asardag AN, Quinn OA, Efimov A, Kang AS ( 2021 ) . Anti-drug antibodies to antibody-based therapeutics in multiple sclerosis . Hum Antibodies

Giovannoni G, Hawkes CH, Lechner-Scott J, Levy M, Yeh EA, Baker D ( 2021 ) . COVID-19 vaccines and multiple sclerosis disease-modifying therapies . Multiple Sclerosis and Related Disorders vol. 53 ,

Patel V, Efimov A, Baker D, Kang AS ( 2021 ) . Immunogenicity of biologics used in the treatment of moderate to severe psoriasis . Human Antibodies vol. 29 , ( 3 ) 171 - 178 .

Hurley MJ, Deacon RMJ, Chan AWE, Baker D, Selwood DL, Cogram P ( 2021 ) . Reversal of behavioural phenotype by the cannabinoid-like compound VSN16R in fragile X syndrome mice . Brain vol. 145 , ( 1 ) 76 - 82 .

Bqain M, Efimov A, Baker D, Kang AS ( 2021 ) . Immunogenicity of biologics used in the treatment of inflammatory bowel disease: A review . Human Antibodies

Baker D, Hadjicharalambous C, Gnanapavan S, Giovannoni G ( 2021 ) . Can rheumatologists stop causing demyelinating disease? . Multiple Sclerosis and Related Disorders vol. 53 ,

Dobson R, ALLEN-PHILBEY K, Giovannoni G, Baker D, Schmierer K ( 2021 ) . Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis . Multiple Sclerosis and Related Disorders

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up (2528) . Neurology vol. 96 , ( 15_supplement )

Schmierer K, Sørensen PS, Baker D ( 2021 ) . Highly effective disease-modifying treatment as initial MS therapy . Current Opinion in Neurology vol. 34 , ( 3 ) 286 - 294 .

Smets I, Reyes S, Baker D, Giovannoni G ( 2021 ) . Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment . Multiple Sclerosis and Related Disorders vol. 50 ,

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 90 - 91 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Cladribine personalised dosing for active multiple sclerosis: BartsMS cohort follow-up . NEUROLOGY . vol. 96 ,

Smets I, Holden D, Bianchi L, Ammoscato F, Allen-Philbey K, Baker D, Turner B, Marta M et al. ( 2021 ) . Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 514 - 515 .

Vickaryous N, Asardag AN, Chance R, Jones M, Bestwick J, Shah SN, George K, Schmierer K et al. ( 2021 ) . Seroconversion following vaccination against SARS-CoV-2 in people with MS: impact of disease modifying therapy . MULTIPLE SCLEROSIS JOURNAL vol. 27 , ( 2_SUPPL ) 775 - 776 .

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2021 ) . Up to 6 years follow-up of people with MS (n=250) receiving cladribine . MULTIPLE SCLEROSIS JOURNAL . vol. 27 , 546 - 547 .

Guo L, Luong V, Gregson A, Baker D, Selwood D, Cordeiro MF ( 2021 ) . VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma . INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE . vol. 62 ,

Thomson A, Dobson R, Baker D, Giovannoni G ( 2020 ) . Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families . Multiple Sclerosis and Related Disorders vol. 47 ,

Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M et al. ( 2020 ) . Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis . Journal of Neurology, Neurosurgery and Psychiatry

Amor S, Fernández Blanco L, Baker D ( 2020 ) . Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage . Clinical & Experimental Immunology vol. 202 , ( 2 ) 193 - 209 .

Mateo-Casas M, Reyes S, De Trane S, Edwards F, Espasandin M, Anjorin G, Baker D, Schmierer K et al. ( 2020 ) . Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not? . eNeurologicalSci vol. 21 ,

Jacobs B, Taylor T, Awad A, Baker D, Giovannoni G, Noyce A, Dobson R ( 2020 ) . Summary-data-based mendelian randomisation prioritises potential druggable targets for Multiple Sclerosis . Brain Communications

Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S, Schmierer K, Giovannoni G et al. ( 2020 ) . COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases . Clinical and Experimental Immunology vol. 202 , ( 2 ) 149 - 161 .

Petrova N, Nutma E, Carassiti D, Newman JR, Amor S, Altmann DR, Baker D, Schmierer K ( 2020 ) . Synaptic Loss in Multiple Sclerosis Spinal Cord . Annals of Neurology vol. 88 , ( 3 ) 619 - 625 .

Baker D ( 2020 ) . Enhanced axonal response of mitochondria to demyelination offers neuroprotection: implications for multiple sclerosis . Acta Neuropathologica

Saxena G, Moore JM, Jones M, Pryce G, Ali L, Leisegang GR, Vijay V, Loveless S et al. ( 2020 ) . Detecting and predicting neutralization of alemtuzumab responses in MS . Neurology Neuroimmunology & Neuroinflammation vol. 7 , ( 4 )

Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders Article 102279 , 102279 - 102279 .

Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G ( 2020 ) . SARS‐CoV‐2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad . Annals of Neurology vol. 87 , ( 6 ) 794 - 797 .

Baker D, Amor S, Kang AS, Schmierer K, Giovannoni G ( 2020 ) . The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic . Multiple Sclerosis and Related Disorders vol. 43 ,

Mateo-Casas M, Reyes S, O'Toole EA, De Trane S, Yildiz O, Allen-Philbey K, Mathews J, Baker D et al. ( 2020 ) . Severe skin reactions associated with cladribine in people with multiple sclerosis . Multiple Sclerosis and Related Disorders . vol. 43 ,

Munger K, Kang A, Baker D, Goodman A, Samkoff L ( 2020 ) . Alemtuzumab Depletion Failure and Neutralizing Anti-Drug Antibodies: a Case Report and Call for Monitoring (1347) . Neurology vol. 94 , ( 15_supplement )

Schmierer K, Baker D ( 2020 ) . B cells and multiple sclerosis spinal cord pathology . Brain Pathology vol. 30 , ( 4 ) 730 - 731 .

Bertrand JA, Schicht M, Stamer WD, Baker D, Sherwood JM, Lütjen-Drecoll E, Selwood DL, Overby DR ( 2020 ) . The beta(4)-Subunit of the Large-Conductance Potassium Ion Channel K(Ca)1.1 Regulates Outflow Facility in Mice . Investigative Ophthalmology and Visual Science vol. 61 , ( 3 )

Ali L, SAXENA G, Jones M, Leisegang G, Gammon L, Gnanapavan S, Giovannoni G, Schmierer K et al. ( 2020 ) . A cell-based assay for the detection of neutralizing antibodies against alemtuzumab . BioTechniques: the journal of laboratory technology for bioresearch

Baker D, Ali L, SAXENA G, Pryce G, Jones M, Schmierer K, Giovannoni G, Gnanapavan S et al. ( 2020 ) . The irony of humanization: Alemtuzumab the first, but one of the most immunogenic, humanized monoclonal antibodies . Frontiers in Immunology vol. 11 , ( 124 )

Saxena GK, Theocharopoulos I, Aziz NT, Jones M, Gnanapavan S, Giovannoni G, Schmierer K, Garnett JA et al. ( 2020 ) . GloBody Technology: Detecting Anti-Drug Antibody against VH/VL domains . Scientific Reports vol. 10 , ( 1 ) Article 1860 ,

Baker D, Pryce G, James LK, Marta M, Schmierer K ( 2020 ) . The ocrelizumab phase II extension trial suggests the potential to improve the risk:benefit balance in multiple sclerosis . Multiple Sclerosis and Related Disorders2020.01.09.20016774 - 2020.01.09.20016774 .

Munger K, Kang A, Baker D, Goodman A, Samkoff L ( 2020 ) . Alemtuzumab depletion failure and neutralizing anti-drug antibodies: a case report and call for monitoring . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 258 - 258 .

Baker DJ ( 2020 ) . Artificial Ventilation, A Basic Clinical Guide . Springer Nature

Allen-Philbey K, De Trane S, Stennett A, Yildiz O, Adams A, Turner B, Marta M, Gnanapavan S et al. ( 2020 ) . Cladribine personalised dosing to treat multiple sclerosis: observations in 208 patients . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 522 - 523 .

Lieberman D, Mangat H, Allen-Philbey K, Baker D, Barkhof F, Chandran S, Chapman C, Chataway J et al. ( 2020 ) . Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS) . MULTIPLE SCLEROSIS JOURNAL . vol. 26 , 212 - 213 .

Yager P, Abe K, Anderson CE, Baker D, Belousov Y, Bishop J, Buser JR, Byrnes SA et al. ( 2020 ) . Low-cost disposable point-of-care devices based on porous materials for rapid detection of pathogens . 21st International Conference on Miniaturized Systems for Chemistry and Life Sciences, MicroTAS 2017 . 97 - 100 .

Baker D, Pryce G, James LK, Schmierer K, Giovannoni G ( 2019 ) . Failed B cell survival factor trials support the importance of memory B cells in multiple sclerosis . European Journal of Neurology vol. 27 , ( 2 ) 221 - 228 .

Farrell R, Baker D ( 2019 ) . An expert opinion: Optimisation of pharmacological management of multiple sclerosis related spasticity . Advances in Clinical Neuroscience and Rehabilitation vol. 18 , ( 5 ) 17 - 19 .

Baker D, Amor S ( 2019 ) . Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model . Annals of Clinical and Translational Neurology

Batcheller L, Baker D ( 2019 ) . Cost of disease modifying therapies for multiple sclerosis: Is front-loading the answer? . Journal of the Neurological Sciences vol. 404 , 19 - 28 .

Tabatabaee S, Baker D, Selwood DL, Whalley BJ, Stephens GJ ( 2019 ) . The Cannabinoid-Like Compound, VSN16R, Acts on Large Conductance, Ca2+-Activated K+ Channels to Modulate Hippocampal CA1 Pyramidal Neuron Firing . Pharmaceuticals vol. 12 , ( 3 )

Baker D, Jacobs BM, Gnanapavan S, Schmierer K, Giovannoni G ( 2019 ) . Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 35 , 19 - 25 .

Pryce G, Baker D ( 2019 ) . CHAPTER 11 Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . Emerging Drugs and Targets for Multiple Sclerosis , Royal Society of Chemistry (RSC)

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner B et al. ( 2019 ) . Cladribine to treat Relapsing and Progressive Multiple Sclerosis - experience in >200 patients (S26.008) . Neurology vol. 92 , ( 15_supplement )

Baker D, Pryce G, Herrod SS, Schmierer K ( 2019 ) . Potential mechanisms of action related to the efficacy and safety of cladribine . Multiple Sclerosis and Related Disorders vol. 30 , 176 - 186 .

Pryce G, Baker D ( 2019 ) . CHAPTER 11: Cannabinoids as a Therapeutic Approach in Multiple Sclerosis . RSC Drug Discovery Series , vol. 2019-January ,

Day AL, Greisen P, Doyle L, Schena A, Stella N, Johnsson K, Baker D, Stoddard B ( 2018 ) . Unintended specificity of an engineered ligand-binding protein facilitated by unpredicted plasticity of the protein fold . Protein Engineering Design and Selection vol. 31 , ( 10 ) 375 - 387 .

Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies . Multiple Sclerosis and Related Disorders vol. 27 , 247 - 253 .

Dubuisson N, Marta M, Gnanapavan S, Turner B, Baker D, Thomson A, Schmierer K, Giovannoni G ( 2018 ) . Inclusion criteria used in trials of people with progressive multiple sclerosis . Mult Scler1352458518803769 - 1352458518803769 .

Maguire JB, Boyken SE, Baker D, Kuhlman B ( 2018 ) . Correction to Rapid Sampling of Hydrogen Bond Networks for Computational Protein Design . Journal of Chemical Theory and Computation vol. 14 , ( 10 ) 5434 - 5434 .

BAKER D, GIOVANNONI G, PRYCE G, AMOR S, SCHMIERER K ( 2018 ) . Learning from other autoimmunities to understand targeting of B cells to control multiple sclerosis . Brain

BO XUENONG, GUSHCHINA S, PRYCE G, YIP P, WU D, PALLIER P, GIOVANNONI G, BAKER D ( 2018 ) . Increased expression of colony‐stimulating factor‐1 in mouse spinal cord with experimental autoimmune encephalomyelitis correlates with microglial activation and neuronal loss . Glia vol. 66 , ( 10 ) 2108 - 2125 .

BAKER D, Pryce, G ( 2018 ) . Oligoclonal bands in multiple sclerosis; functional significance and therapeutic implications. Does the specificity matter? . multiple sclerosis and related disorders

Bavinton BR, Pinto AN, Phanuphak N, Grinsztejn B, Prestage GP, Zablotska-Manos IB, Jin F, Fairley CK et al. ( 2018 ) . Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study . The Lancet HIV vol. 5 , ( 8 ) e438 - e447 .

Jacobs BM, Ammoscato F, Giovannoni G, Baker D, Schmierer K ( 2018 ) . Cladribine: mechanisms and mysteries in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry vol. 89 , ( 12 )

Mao Z, Álvarez-Gonzalez C, De Trane S, Yildiz O, Albor C, Doctor G, Soon D, Pepper G et al. ( 2018 ) . Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings? . Multiple Sclerosis Journal - Experimental, Translational and Clinical vol. 4 , ( 2 ) 2055217318783767 - 2055217318783767 .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine . Multiple Sclerosis and Related Disorders vol. 24 , 20 - 27 .

Nicholson T, Church C, Baker DJ, Jones SW ( 2018 ) . The role of adipokines in skeletal muscle inflammation and insulin sensitivity . Journal of Inflammation vol. 15 , ( 1 )

Ceronie B, Dubuisson N, Ammoscato F, Baker D, Giovannoni G, Schmierer K ( 2018 ) . Memory B Cells: Toward a Unified Therapeutic Target for Effective Immunotherapy in Multiple Sclerosis (P5.365) . Neurology . vol. 90 ,

Ceronie B, Jacobs BM, Baker D, Dubuisson N, Mao Z, Ammoscato F, Lock H, Longhurst HJ et al. ( 2018 ) . Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells . Journal of Neurology vol. 265 , ( 5 ) 1199 - 1209 .

Ruz‐Maldonado I, Pingitore A, Liu B, Atanes P, Huang GC, Baker D, Alonso FJ, Bermúdez‐Silva FJ et al. ( 2018 ) . Cover Image, Volume 20, Issue 4 . Diabetes Obesity and Metabolism vol. 20 , ( 4 ) i - i .

Dubuisson N, Baker D, Kang AS, Pryce G, Marta M, Visser LH, Hofmann WE, Gnanapavan S et al. ( 2018 ) . Alemtuzumab depletion failure can occur in multiple sclerosis . Immunology vol. 154 , ( 2 ) 253 - 260 .

Ruz-Maldonado I, Liu B, Atanes P, Pingitore A, Huang GC, Baker D, Persaud SJ ( 2018 ) . CB1 antagonists SR141617A and AM251 stimulate insulin secretion from mouse and human islets . DIABETIC MEDICINE . vol. 35 , 47 - 47 .

De Trane S, Mao Z, Alvarez-Gonzalez C, Allen-Philbey K, Yildiz O, Campion T, Adams A, Turner BP et al. ( 2018 ) . Cladribine personalised dosing in people with MS (n>200) - four years experience in clinical care .

Yildiz O, Mao Z, Adams A, Dubuisson N, Allen-Philbey K, Giovannoni G, Malaspina A, Baker D et al. ( 2018 ) . Elevated neurofilament light chain levels in progressive multiple sclerosis effectively reduced by cladribine treatment . MULTIPLE SCLEROSIS JOURNAL . vol. 24 , 949 - 949 .

Ruz-Maldonado I, Pingitore A, Liu B, Atanes P, Huang GC, Baker D, Alonso FJ, Bermúdez-Silva FJ et al. ( 2017 ) . LH‐21 and abnormal cannabidiol improve β‐cell function in isolated human and mouse islets through GPR55‐dependent and ‐independent signalling . Diabetes Obes Metab vol. 20 , ( 4 ) 930 - 942 .

Dubuisson N, Bauer A, Marta M, Gnanapavan S, Turner B, Baker D, Giovannoni G, Schmierer K et al. ( 2017 ) . PO124 Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 ,

Schmierer K, Marta M, Pryce G, Giovannoni G, Baker D ( 2017 ) . PO150 Memory b cells are key for immunotherapy in multiple sclerosis . Journal of Neurology Neurosurgery & Psychiatry . vol. 88 , a52 - a52 .

Baker D, Giovannoni G, Schmierer K ( 2017 ) . Marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment . Multiple Sclerosis and Related Disorders

BAKER D ( 2017 ) . SPATIAL DISTRIBUTION OF THE CANNABINOID TYPE 1 AND CAPSAICIN RECEPTORS MAY CONTRIBUTE TO THE COMPLEXITY OF THEIR CROSSTALK . Scientific Reports

Pryce G, Baker D ( 2017 ) . Antidote to cannabinoid intoxication: the CB1 receptor inverse agonist, AM251, reverses hypothermic effects of the CB1 receptor agonist, CB‐13, in mice . British Journal of Pharmacology vol. 174 , ( 21 ) 3790 - 3794 .

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may affect MS via B-cell depletion (vol 4, e360, 2017) . NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION vol. 4 , ( 5 )

Puentes F, van der Star BJ, Boomkamp SD, Kipp M, Boon L, Bosca I, Raffel J, Gnanapavan S et al. ( 2017 ) . Neurofilament light as an immune target for pathogenic antibodies . Immunology vol. 152 , ( 4 ) 580 - 588 .

Dubuisson N, Bauer A, Buckley M, Gilbert R, Paterson A, Marta M, Gnanapavan S, Turner B et al. ( 2017 ) . Validation of an environmentally-friendly and affordable cardboard 9-hole peg test . Multiple Sclerosis and Related Disorders vol. 17 , 172 - 176 .

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K ( 2017 ) . Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab . JAMA Neurol vol. 74 , ( 8 ) 961 - 969 .

Afolabi D, Albor C, Zalewski L, Altmann DR, Baker D, Schmierer K ( 2017 ) . Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis . Mult Scler1352458517726380 - 1352458517726380 .

BAKER D ( 2017 ) . Big conductance calcium-activated potassium channel openers control spasticity without sedation . British Journal of Pharmcology

Dubuisson N, Baker D, Thomson A, Marta M, Gnanapavan S, Turner B, Giovannoni G, Schmierer K ( 2017 ) . Disease modification in advanced MS: Focus on upper limb function . Multiple Sclerosis Journal vol. 23 , ( 14 ) 1956 - 1957 .

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K ( 2017 ) . Both cladribine and alemtuzumab may effect MS via B-cell depletion . Neurology Neuroimmunology & Neuroinflammation vol. 4 , ( 4 )

BAKER D, SCHMIERER K, Herrod S, Alvarez Gonzalez C, Zalewski L, Albor C ( 2017 ) . Both cladribine and alemtuzumab may effect multiple sclerosis via B cell depletion . Neurology: Neuroimmunology and Neuroinflammation vol. 4 , ( 4 )

Alvarez-Gonzalez C, Adams A, Mathews J, Turner BP, Giovannoni G, Baker D, Schmierer K ( 2017 ) . Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis . Annals of Clinical and Translational Neurology

Petrova N, Carassiti D, Altmann DR, Baker D, Schmierer K ( 2017 ) . Axonal loss in the multiple sclerosis spinal cord revisited . Brain Pathology vol. 28 , ( 3 ) 334 - 348 .

BAKER D, Giovannoni G, Sefia E, Pryce G, Meier U ( 2017 ) . Depletion of CD20 B cells fails to inhibit relapsing mouse experimental autoimmune encephalomyelitis . Multiple Sclerosis and Related Disorders

Schmierer K, Herrod S, Alvarez-Gonzalez C, Baker D ( 2017 ) . Cladribine versus Alemtuzumab: efficacy and autoimmunity in multiple sclerosis induction treatment (P6.383) . Neurology . vol. 88 ,

Thomson A, Raciborska D, Baker D, Giovannoni G ( 2017 ) . How to start a blog . Pract Neurol vol. 17 , ( 3 ) 224 - 228 .

Baumberg I, Baker D, Wołoszyn P, Andres J, Kopacki W, Krawczyk P, Gaszyński W ( 2017 ) . The timing of chest compressions and artificial ventilation: A re-appraisal . The American Journal of Emergency Medicine vol. 35 , ( 10 ) 1569 - 1571 .

Lecommandeur E, Baker D, Cox TM, Nicholls AW, Griffin JL ( 2017 ) . Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease . Journal of Lipid Research vol. 58 , ( 7 ) 1306 - 1314 .

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K ( 2017 ) . Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis . EBioMedicine vol. 16 , 41 - 50 .

Giovannoni G, Cutter G, Pia-Sormani M, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D et al. ( 2017 ) . Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses . Multiple Sclerosis and Related Disorders vol. 12 , 70 - 78 .

von Kutzleben S, Pryce G, Giovannoni G, Baker D ( 2017 ) . Depletion of CD52‐positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune‐tolerance promoting CD8 T‐cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis . Immunology vol. 150 , ( 4 ) 444 - 455 .

Baker D, Kang AS, Gnanapavan S, Giovannoni G, Schmierer K ( 2017 ) . A central role of B cells in MS control and causing autoimmunity after alemtuzumab . MULTIPLE SCLEROSIS JOURNAL . vol. 23 , 336 - 336 .

Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Turner BP, Baker D, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . TREATING MULTIPLE SCLEROSIS WITH CLADRIBINE . JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 87 ,

Williams T, Pryce G, Giovannoni G, Selwood D, Baker D ( 2016 ) . VSN16R-A NOVEL TREATMENT FOR SPASTICITY IN EXPERIMENTAL MULTIPLE SCLEROSIS . vol. 87 , is. 12 , Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,

Baker D, Anandhakrishnan A, Tuite-Dalton KA, Lockart–Jones H, Middleton RM, Ford DV, Crowe C, Giovannoni G ( 2016 ) . How to refer to people with disease in research outputs: The disconnection between academic practise and that preferred by people with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 10 , 127 - 133 .

Liu B, Song S, Ruz-Maldonado I, Pingitore A, Huang GC, Baker D, Jones PM, Persaud SJ ( 2016 ) . GPR55‐dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans . Diabetes Obesity and Metabolism vol. 18 , ( 12 ) 1263 - 1273 .

Horowitz S, Koepnick B, Martin R, Tymieniecki A, Winburn AA, Cooper S, Flatten J, Rogawski DS et al. ( 2016 ) . Determining crystal structures through crowdsourcing and coursework . Nature Communications vol. 7 , ( 1 )

Agahozo MC, Peferoen L, Baker D, Amor S ( 2016 ) . CD20 therapies in multiple sclerosis and experimental autoimmune encephalomyelitis – Targeting T or B cells? . Multiple Sclerosis and Related Disorders vol. 9 , Article C , 110 - 117 .

Thomson A, Giovannoni G, Marta M, Gnanpavan S, Turner B, Baker D, Schmierer K ( 2016 ) . Importance of upper limb function in advanced multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 676 - 676 .

Rejdak K, Mitosek-Szewczyk K, Prus K, Trzciniecka O, Baker D, Schmierer K, Stelmasiak Z ( 2016 ) . Induction therapy of relapsing secondary multiple sclerosis using generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) 2016 vol. 22 , 593 - 594 .

Petrova N, Carassiti D, Scaravilli F, Baker D, Schmierer K ( 2016 ) . Synaptic loss in the MS spinal cord: a key driver of disease progression? . MULTIPLE SCLEROSIS JOURNAL . Conference: ECTRIMS 2016 Committees ( UCL Institute of Neurology, London, UK ) from: 14/09/2016 to: 17/09/2016 , vol. 22 , 80 - 80 .

Alvarez-Gonzalez C, Allen-Philbey K, Mathews J, Espasandin M, Turner BP, Gnanapavan S, Marta M, Giovannoni G et al. ( 2016 ) . Treating multiple sclerosis with generic cladribine . MULTIPLE SCLEROSIS JOURNAL . Conference: MSLondon (ACTRIMS/ECTRIMS) vol. 22 , 604 - 605 .

Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN et al. ( 2016 ) . Predicting Alzheimer disease from a blood-based biomarker profile . Neurology vol. 87 , ( 11 ) 1093 - 1101 .

Peferoen LAN, Breur M, van de Berg S, Peferoen-Baert R, Boddeke EHWGM, van der Valk P, Pryce G, van Noort JM et al. ( 2016 ) . Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice . Immunology vol. 149 , ( 2 ) 146 - 156 .

Baird AL, Hye A, Westwood S, Ashton NJ, Liu BY, Bazenet C, Kiddle SJ, Ward M et al. ( 2016 ) . S4‐01‐01: Cross‐Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau . Alzheimer's & Dementia vol. 12 , ( 7S_Part_6 ) p321 - p321 .

Sevastou I, Pryce G, Baker D, Selwood DL ( 2016 ) . Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing . PLOS ONE vol. 11 , ( 6 ) e0157754 - e0157754 .

Baker DJ, Bradley N, Dobney A, Murray V, Meara JR, O’Hagan J, McColl NP, Cox CL ( 2016 ) . Human physiology, hazards and health risks . Clay’s Handbook of Environmental Health, 21st Edition ,

Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L et al. ( 2015 ) . Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis* . Journal of Biological Chemistry vol. 291 , ( 9 ) 4356 - 4373 .

Ummenthum K, Peferoen LAN, Finardi A, Baker D, Pryce G, Mantovani A, Bsibsi M, Bottazzi B et al. ( 2015 ) . Pentraxin‐3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease . European Journal of Immunology vol. 46 , ( 3 ) 701 - 711 .

Baker DJ ( 2015 ) . Chapter 16 Acute Lung Injury Following Inhalation of Irritant Products of Combustion . Toxicology, Survival and Health Hazards of Combustion Products , Royal Society of Chemistry (RSC)

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, Juliusson G, Baker D et al. ( 2015 ) . No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine . Neurology Neuroimmunology & Neuroinflammation vol. 2 , ( 6 )

Park H, DiMaio F, Baker D ( 2015 ) . CASP11 refinement experiments with ROSETTA . Proteins Structure Function and Bioinformatics vol. 84 , ( S1 ) 314 - 322 .

Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical and Experimental Immunology vol. 180 , ( 3 ) 432 - 441 .

Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP ( 2015 ) . Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Clinical & Experimental Immunology vol. 180 , ( 3 ) 432 - 441 .

Pryce G, Baker D ( 2015 ) . Cannabinoids fail to show evidence of slowing down the progression of multiple sclerosis . BMJ Evidence-Based Medicine vol. 20 , ( 4 )

Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2015 ) . Correction to Imidazol-1-ylethylindazole Voltage-Gated Sodium Channel Ligands Are Neuroprotective during Optic Neuritis in a Mouse Model of Multiple Sclerosis . Journal of Medicinal Chemistry vol. 58 , ( 8 ) 3637 - 3637 .

Pakpoor J, Disanto G, Altmann D, Pavitt S, Turner B, Marta M, Juliusson G, Baker D et al. ( 2015 ) . Cancer Risk is Not Increased in People with Relapsing Multiple Sclerosis Taking Cladribine (P7.011) . Neurology vol. 84 , ( 14_supplement )

Ashton NJ, Kiddle SJ, Graf J, Ward M, Baird AL, Hye A, Westwood S, Wong KV et al. ( 2015 ) . Blood protein predictors of brain amyloid for enrichment in clinical trials? . Alzheimer's & Dementia Diagnosis Assessment & Disease Monitoring vol. 1 , ( 1 ) 48 - 60 .

Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, van der Pol SM, Hirst MC et al. ( 2015 ) . Brain Endothelial miR-146a Negatively Modulates T-Cell Adhesion through Repressing Multiple Targets to Inhibit NF-κB Activation . Cerebrovascular and Brain Metabolism Reviews vol. 35 , ( 3 ) 412 - 423 .

Biela A, Watkinson M, Meier UC, Baker D, Giovannoni G, Becer CR, Krause S ( 2015 ) . Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy . Biosensors and Bioelectronics vol. 68 , 660 - 667 .

Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, Van Der Pol SMA, Hirst MC et al. ( 2015 ) . Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation . Journal of Perinatology vol. 35 , ( 3 ) 412 - 423 .

Pryce G, Baker D ( 2015 ) . Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis . Handbook of Experimental Pharmacology vol. 231 , 213 - 231 .

Vainchtein I, Vinet J, Al-Izki S, Pryce G, Grit C, Brouwer N, Amor S, Baker D et al. ( 2015 ) . Microglia are involved in apoptotic clearance during chronic-relapsing EAE . GLIA . vol. 63 , E353 - E353 .

Baker D, Amor S ( 2015 ) . Mouse models of multiple sclerosis: lost in translation? . Current Pharmaceutical Design vol. 21 , ( 18 ) 2440 - 2452 .

Ruz Maldonado I, Pingitore A, Liu B, Huang GC, Baker D, Bermudez-Silva FJ, Persaud SJ ( 2015 ) . Stimulation of insulin secretion by cannabinoid ligands LH-21 and Abn-CBD in mouse and human islets: evaluation of the role of GPR55 . DIABETOLOGIA . vol. 58 , S86 - S86 .

Giovannoni G, Baker D, Schmierer K ( 2015 ) . The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? . Multiple Sclerosis and Related Disorders vol. 4 , ( 1 ) 3 - 5 .

Pryce G, Riddall DR, Selwood DL, Giovannoni G, Baker D ( 2014 ) . Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids . Journal of Neuroimmune Pharmacology vol. 10 , ( 2 ) 281 - 292 .

Von Kutzleben S, Pryce G, Chretien N, Turner M, Siders W, Baker D ( 2014 ) . Inhibition of relapsing experimental autoimmune encephalomyelitis in Biozzi ABH mice using a mouse CD52-specific monoclonal antibody . Journal of Neuroimmunology . vol. 275 ,

Giovannoni G, Baker D, Schmierer K ( 2014 ) . Simvastatin in patients with progressive multiple sclerosis . Lancet vol. 384 , ( 9947 )

Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner B, Calado-Marta M, Juliusson G, Baker D et al. ( 2014 ) . CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE . Journal of Neurology Neurosurgery & Psychiatry . vol. 85 , e4 - e4 .

Amor S, van der Star BJ, Bosca I, Raffel J, Gnanapavan S, Watchorn J, Kuhle J, Giovannoni G et al. ( 2014 ) . Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis . Mult Scler vol. 20 , ( 10 ) 1355 - 1362 .

Graham DP, Rezai A, Baker D, Smith PA, Watts JF ( 2014 ) . The development and scalability of a high strength, damage tolerant, hybrid joining scheme for composite–metal structures . Composites Part A Applied Science and Manufacturing vol. 64 , 11 - 24 .

Woodhead J, Yang K, Brouwer K, Siler S, Stahl S, Ambroso J, Baker D, Watkins P et al. ( 2014 ) . Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid–Mediated DILI . CPT Pharmacometrics & Systems Pharmacology vol. 3 , ( 7 ) 1 - 8 .

Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE et al. ( 2014 ) . MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation . FASEB J vol. 28 , ( 6 ) 2551 - 2565 .

Browne L, Lidster K, Al-Izki S, Clutterbuck L, Posada C, Chan AWE, Riddall D, Garthwaite J et al. ( 2014 ) . Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis . J Med Chem vol. 57 , ( 7 ) 2942 - 2952 .

Baker DJ, Richards G ( 2014 ) . On the delivery of weather services and parallels for the development of operational forest carbon measurement, reporting and verification systems . Carbon Management vol. 2 , ( 5 ) 567 - 573 .

Baker DJ, Atkinson AM, Wilkinson GP, Coope GJ, Charles AD, Leighton B ( 2014 ) . Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1629 - 1641 .

Baker DJ, Wilkinson GP, Atkinson AM, Jones HB, Coghlan M, Charles AD, Leighton B ( 2014 ) . Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes . British Journal of Pharmacology vol. 171 , ( 7 ) 1642 - 1654 .

Puentes F, Topping J, Kuhle J, van der Star BJ, Douiri A, Giovannoni G, Baker D, Amor S et al. ( 2014 ) . Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis . J Neurol Neurosurg Psychiatry vol. 85 , ( 3 ) 274 - 278 .

Dua P, Warnes G, Chruch A, Martino D, Baker D, Giovannoni G, Meier UC ( 2014 ) . Functional effects of anti-neuronal antibodies from patients with Tourette's syndrome and disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 20 , ( 1 ) 17 - 18 .

Pakpoor J, Nyein S, Disanto G, Nwosu A, Baker D, Giovannoni G ( 2014 ) . A global analysis of the use of social media to discuss multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL . vol. 20 , 334 - 335 .

Pryce G, Visintin C, Ramagopalan SV, Al-Izki S, De Faveri LE, Nuamah RA, Mein CA, Montpetit A et al. ( 2014 ) . Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists . FASEB J vol. 28 , ( 1 ) 117 - 130 .

Baker D, Amor S ( 2014 ) . Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely . Multiple Sclerosis and Related Disorders

Whyte L, Khalid A, Finnie G, Chiu S, Baker D, Aspden R, Ross R ( 2014 ) . GPR55 Regulates Peak Bone Mass and Steroid Hormone Levels in Male Mice . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 29 , S409 - S409 .

Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . GPR55 deletion is coupled to impaired insulin secretion and reduced islet cell turnover . DIABETIC MEDICINE vol. 31 , 9 - 9 .

Baker D, Pell C, Donovan B ( 2014 ) . HIV infection as a chronic disease: Optimising outcomes . Medicine Today vol. 15 , ( 2 ) 16 - 26 .

Amor S, Peferoen LAN, Vogel DYS, Breur M, van der Valk P, Baker D, Van Noort JM ( 2014 ) . Inflammation in neurodegenerative diseases - an update . Immunology vol. 142 , ( 2 ) 151 - 166 .

Liu B, Song S, Baker D, Hassan Z, Drynda RL, Bowe JE, Jones PM, Persaud SJ ( 2014 ) . Knockout of GPR55 impairs insulin secretion and reduces islet cell turnover . DIABETOLOGIA vol. 57 , S49 - S49 .

Mullen L, Rigby A, Sclanders M, Adams G, Mittal G, Colston J, Fatah R, Subang C et al. ( 2014 ) . Latency can be conferred to a variety of cytokines by fusion with latency-associated peptide from TGF-β . Expert Opin Drug Deliv vol. 11 , ( 1 ) 5 - 16 .

Mullen L, Adams G, Layward L, Vessillier S, Annenkov A, Mittal G, Rigby A, Sclanders M et al. ( 2014 ) . Latent cytokines for targeted therapy of inflammatory disorders . Expert Opin Drug Deliv vol. 11 , ( 1 ) 101 - 110 .

Al-Izki S, Pryce G, Hankey DJR, Lidster K, von Kutzleben SM, Browne L, Clutterbuck L, Posada C et al. ( 2014 ) . Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis . Brain vol. 137 , ( Pt 1 ) 92 - 108 .

Baker D, Pepper G, Yauner F, Giovannoni G ( 2014 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 3 , ( 1 ) 31 - 33 .

Song S, Liu B, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2014 ) . Specificity of GPR55 agonists and antagonist in the regulation of calcium handling and insulin secretion by mouse islets . DIABETIC MEDICINE vol. 31 , 32 - 32 .

Baker D, Lidster K, Sottomayor A, Amor S ( 2014 ) . Two years later: journals are not yet enforcing the ARRIVE guidelines on reporting standards for pre-clinical animal studies . PLoS Biol vol. 12 , ( 1 )

Hampton DW, Serio A, Pryce G, Al-Izki S, Franklin RJ, Giovannoni G, Baker D, Chandran S ( 2013 ) . Neurodegeneration progresses despite complete elimination of clinical relapses in a mouse model of multiple sclerosis . Acta Neuropathologica Communications vol. 1 , ( 1 )

Pryce G, Cabranes A, Fernández-Ruiz J, Bisogno T, Di Marzo V, Long JZ, Cravatt BF, Giovannoni G et al. ( 2013 ) . Control of experimental spasticity by targeting the degradation of endocannabinoids using selective fatty acid amide hydrolase inhibitors . Mult Scler vol. 19 , ( 14 ) 1896 - 1904 .

Delarasse C, Smith P, Baker D, Amor S ( 2013 ) . Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice . Immunology vol. 140 , ( 4 ) 456 - 464 .

Fishpool DT, Rezai A, Baker D, Ogin SL, Smith PA ( 2013 ) . Interlaminar toughness characterisation of 3D woven carbon fibre composites . Plastics, Rubber and Composites vol. 42 , ( 3 ) 108 - 114 .

James E, Dobson R, Kuhle J, Baker D, Giovannoni G, Ramagopalan SV ( 2013 ) . The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis . Mult Scler vol. 19 , ( 12 ) 1571 - 1579 .

Puentes F, van der Star BJ, Victor M, Kipp M, Beyer C, Peferoen-Baert R, Ummenthum K, Pryce G et al. ( 2013 ) . Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis . Journal of Neuroinflammation vol. 10 ,

Richter F, Baker D ( 2013 ) . Computational protein design for synthetic biology . Synthetic Biology: Tools and Applications ,

Baker D, Lidster K, Al-Izki S, Pryce G, Giovannoni G ( 2013 ) . Animal models of progressive disability in MS . IRISH JOURNAL OF MEDICAL SCIENCE vol. 182 , S5 - S6 .

Di Filippo M, Chiasserini D, Gardoni F, Viviani B, Tozzi A, Giampa C, Costa C, Tantucci M et al. ( 2013 ) . Effects of central and peripheral inflammation on hippocampal synaptic plasticity . NEUROBIOLOGY OF DISEASE vol. 52 , 229 - 236 .

Liu B, Song S, Baker D, Bowe J, Hassan Z, Drynda R, Jones P, Persaud S ( 2013 ) . GPR55 deletion is coupled to impaired glucose tolerance and increased islet cell apoptosis . DIABETOLOGIA . vol. 56 , S46 - S46 .

Sisay S, Pryce G, Jackson SJ, Tanner C, Ross RA, Michael GJ, Selwood DL, Giovannoni G et al. ( 2013 ) . Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis . PLoS One vol. 8 , ( 10 )

Baker D, Pepper G, Yauner F, Giovannoni G ( 2013 ) . MSer - A new, neutral descriptor for someone with multiple sclerosis . Multiple Sclerosis and Related Disorders

Lidster K, Jackson SJ, Ahmed Z, Munro P, Coffey P, Giovannoni G, Baker MD, Baker D ( 2013 ) . Neuroprotection in a novel mouse model of multiple sclerosis . PLoS One vol. 8 , ( 11 )

Khoury GA, Liwo A, Khatib F, Zhou H, Chopra G, Bacardit J, Bortot LO, Faccioli RA et al. ( 2013 ) . Wefold: A collaborative protein structure prediction experiment . Computational Molecular Science and Engineering Forum 2013 - Core Programming Area at the 2013 AIChE Annual Meeting: Global Challenges for Engineering a Sustainable Future . 182 - 184 .

Baker DJ ( 2012 ) . Cloudy Forecast for Weather Satellite Data . Science vol. 338 , ( 6113 ) 1419 - 1419 .

Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Reproducibility: Research-reporting standards fall short . Nature vol. 492 , ( 7427 )

Baker D, Lidster K, Sottomayor A, Amor S ( 2012 ) . Research-reporting standards fall short . Nature vol. 492 , ( 7427 ) 41 - 41 .

Malich G, Coupland R, Donnelly S, Baker D ( 2012 ) . A proposal for field-level medical assistance in an international humanitarian response to chemical, biological, radiological or nuclear events . Emergency Medicine Journal vol. 30 , ( 10 )

Baker D, Amor S ( 2012 ) . Multiple sclerosis - from bench to bedside . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 495 - 496 .

Lidster K, Baker D ( 2012 ) . Optical coherence tomography detection of neurodegeneration in multiple sclerosis . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 518 - 527 .

Pryce G, Baker D ( 2012 ) . Potential control of multiple sclerosis by cannabis and the endocannabinoid system . CNS Neurol Disord Drug Targets vol. 11 , ( 5 ) 624 - 641 .

Amor S, Baker D ( 2012 ) . Checklist for reporting and reviewing studies of experimental animal models of multiple sclerosis and related disorders . Multiple Sclerosis and Related Disorders vol. 1 , ( 3 ) 111 - 115 .

Baker D ( 2012 ) . Civilian Exposure to Toxic Agents: Emergency Medical Response . Prehospital and Disaster Medicine vol. 19 , ( 2 ) 174 - 178 .

Baker D ( 2012 ) . Improving Decontamination Procedures: A Priority for Chemical Incident Management . Prehospital and Disaster Medicine vol. 25 , ( 5 ) 440 - 441 .

Gnanapavan S, Grant D, Pryce G, Jackson S, Baker D, Giovannoni G ( 2012 ) . Neurofilament a biomarker of neurodegeneration in autoimmune encephalomyelitis . Autoimmunity vol. 45 , ( 4 ) 298 - 303 .

Baker D, Pryce G, Jackson SJ, Bolton C, Giovannoni G ( 2012 ) . The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis . Multiple Sclerosis and Related Disorders vol. 1 , ( 2 ) 64 - 75 .

Dua P, Meier UC, Baker D, Giovannoni G ( 2012 ) . Functional effects of anti-neuronal antibodies in patients with encephalitis lethargica and other related disorders associated with streptococcal infection . Neurology Psychiatry and Brain Research vol. 18 , ( 2 )

Baker D, Amor S ( 2012 ) . Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis . J Neuroimmunol vol. 242 , ( 1-2 ) 78 - 83 .

van der Star BJ, Vogel DYS, Kipp M, Puentes F, Baker D, Amor S ( 2012 ) . <i>In Vitro</i> and <i>In Vivo</i> Models of Multiple Sclerosis . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 570 - 588 .

Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, de Vries HE, Hirst MC et al. ( 2012 ) . Endothelial miR-155 promotes blood brain barrier dysfunction in neuroinflammation . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 3 - 4 .

Kipp M, Van Der Star B, Vogel DYS, Puentes F, Van Der Valk P, Baker D, Amor S ( 2012 ) . Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 15 - 28 .

Sher F, Amor S, Gerritsen W, Baker D, Jackson SL, Boddeke E, Copray S ( 2012 ) . Intraventricularly Injected Olig2-NSCs Attenuate Established Relapsing-Remitting EAE in Mice . CELL TRANSPLANTATION vol. 21 , ( 9 ) 1883 - 1897 .

Song S, Liu B, Baker D, Huang GC, Amiel SA, King AJ, Bowe JE, Jones PM et al. ( 2012 ) . Islet GPR55 is coupled to increased insulin secretion and decreased apoptosis . DIABETOLOGIA vol. 55 , S163 - S163 .

van Noort JM, Baker D, Amor S ( 2012 ) . Mechanisms in the Development of Multiple Sclerosis Lesions: Reconciling Autoimmune and Neurodegenerative Factors . CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS vol. 11 , ( 5 ) 556 - 569 .

van der Star B, Puentes F, Gerritsen W, Huizinga R, Reijerkerk A, van der Valk P, Baker D, Amor S ( 2012 ) . Neuronal specific T cells are pathogenic in Biozzi mice - Implications for MS . JOURNAL OF NEUROIMMUNOLOGY . vol. 253 , 155 - 155 .

Li C, Bowe JE, Baker D, Jones PM, Persaud SJ ( 2012 ) . PS 014 Beta cell GPCRs and other signalling mechanisms . DIABETOLOGIA vol. 55 , S163 - S163 .

Al-Izki S, Pryce G, O'Neill JK, Butter C, Giovannoni G, Amor S, Baker D ( 2012 ) . Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse . Multiple Sclerosis and Related Disorders vol. 1 , ( 1 ) 29 - 38 .

Fox RJ, Thompson A, Baker D, Baneke P, Brown D, Browne P, Chandraratna D, Ciccarelli O et al. ( 2012 ) . Setting a research agenda for progressive multiple sclerosis: The International Collaborative on Progressive MS . MULTIPLE SCLEROSIS JOURNAL vol. 18 , ( 11 ) 1534 - 1540 .

Ayoub SS, Pryce G, Seed MP, Bolton C, Flower RJ, Baker D ( 2011 ) . Paracetamol-induced hypothermia is independent of cannabinoids and transient receptor potential vanilloid-1 and is not mediated by AM404 . Drug Metab Dispos vol. 39 , ( 9 ) 1689 - 1695 .

Al-Izki S, Pryce G, Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis . Mult Scler vol. 17 , ( 8 ) 939 - 948 .

Jackson SJ, Giovannoni G, Baker D ( 2011 ) . Fingolimod modulates microglial activation to augment markers of remyelination . J Neuroinflammation vol. 8 ,

Baker D, Gerritsen W, Rundle J, Amor S ( 2011 ) . Critical appraisal of animal models of multiple sclerosis . Mult Scler vol. 17 , ( 6 ) 647 - 657 .

Graham DP, Rezai A, Baker D, Smith PA, Watts JF ( 2011 ) . A hybrid joining scheme for high strength multimaterial joints . ICCM International Conferences on Composite Materials .

Puentes F, van der Star B, Huizinga R, Gerritsen W, van der Valk P, Baker D, Amor S ( 2011 ) . Autoimmunity to axonal proteins in multiple sclerosis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S329 - S329 .

Andreou AP, Supronsinchai W, Lasalandra M, Baker D, Goadsby PJ ( 2011 ) . Cannabinoid mechanisms of acetaminophen within the trigeminal thalamus . CEPHALALGIA . vol. 31 , 8 - 8 .

Baker DJ, Nurok M ( 2011 ) . Chemical and biologic warfare agents: An introduction for anesthesiologists . Essential Clinical Anesthesia ,

Jackson S, Giovannoni G, Baker D ( 2011 ) . Fingolimod (FTY720) modulates microglial activation to augment markers of remyelination . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S210 - S210 .

Lidster K, Jackson S, Coffey P, Baker M, Garthwaite J, Selwood D, Giovannoni G, Baker D ( 2011 ) . Neuroprotection in a novel optic neuritis model . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S435 - S435 .

Fishpool DT, Rezai A, Baker D, Ogin SL, Smith PA ( 2011 ) . Preferential energy absorbing interfacesfor ballistic and structural applications . ICCM International Conferences on Composite Materials .

Al-Izki S, Pryce G, Amor S, Gerritsen W, Garthwaite J, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of neuroprotection to MS lesions: sodium channel blockers in experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S209 - S210 .

Pryce G, Visintin C, Lutz B, Marsicano G, Giovannoni G, Selwood DL, Baker D ( 2011 ) . Selective targeting of spasticity by CNS-excluded cannabinoids . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S247 - S247 .

Baker D, Pryce G, Visintin C, Pertwee RG, Tanner C, Ross R, Irving A, Sisay S et al. ( 2011 ) . VSN16R a novel agent for the control of spasticity . MULTIPLE SCLEROSIS JOURNAL vol. 17 , S243 - S243 .

Baker D, Amor S ( 2010 ) . Editorial: Quality control of experimental autoimmune encephalomyelitis . Multiple Sclerosis vol. 16 , ( 9 ) 1025 - 1027 .

Baker D, Amor S ( 2010 ) . Quality control of experimental autoimmune encephalomyelitis . Mult Scler vol. 16 , ( 9 ) 1025 - 1027 .

Baker DJ, Richards G, Grainger A, Gonzalez P, Brown S, DeFries R, Held A, Kellndorfer J et al. ( 2010 ) . Achieving forest carbon information with higher certainty: A five-part plan . Environmental Science & Policy vol. 13 , ( 3 ) 249 - 260 .

Amor S, Puentes F, Baker D, van der Valk P ( 2010 ) . Inflammation in neurodegenerative diseases . IMMUNOLOGY vol. 129 , ( 2 ) 154 - 169 .

Lapa e Silva JR, Pretolani M, Bachelet CM, Baker D, Scheper R, Vargaftig BB ( 2009 ) . Booster-Dependent Alterations of the Subsets of T Lymphocytes and Eosinophils in the Bronchi of Immunized Guinea Pigs . International Archives of Allergy and Immunology vol. 99 , ( 2-4 ) 350 - 353 .

Goto K, Kawanabe K, Kowalski R, Baker D, Nakamura T ( 2009 ) . Bonding ability evaluation of bone cement on the cortical surface of rabbit’s tibia . Journal of Materials Science: Materials in Medicine vol. 21 , ( 1 ) 139 - 146 .

Kimber I, Foster JR, Baker D, Turk JL ( 2009 ) . Selective Impairment of T Lymphocyte Activation following Contact Sensitization with Oxazolone . International Archives of Allergy and Applied Immunology vol. 95 , ( 2-3 ) 142 - 148 .

Kimber I, Bentley AN, Ward RK, Baker D, Turk JL ( 2009 ) . Antigen-Restricted Antigenic Competition Induced by 2,4-Dinitrochlorobenzene: Association with Depression of Lymphocyte Proliferation . International Archives of Allergy and Applied Immunology vol. 91 , ( 3 ) 315 - 322 .

Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid Receptor Type 1 Protects against Age-Related Osteoporosis by Regulating Osteoblast and Adipocyte Differentiation in Marrow Stromal Cells . CELL METAB vol. 10 , ( 2 ) 139 - 147 .

Healey DG, Baker D, Gschmeissner SE, Turk JL ( 2009 ) . An Antigenic Determinant Common to Lymphocytes and Langerhans Cells of the Guinea Pig . International Archives of Allergy and Applied Immunology vol. 82 , ( 2 ) 120 - 124 .

Baker D, Healey DG, Verghese S, Schäfer H, Turk JL ( 2009 ) . Phenotypic Analysis of Guinea Pig Langerhans Cells with Antibodies Directed against Leucocyte Surface Antigens . International Archives of Allergy and Applied Immunology vol. 86 , ( 3 ) 350 - 355 .

Al-Izki S, Pryce G, Giovannoni G, Baker D ( 2009 ) . Evaluating potential therapies for bladder dysfunction in a mouse model of multiple sclerosis with high-resolution ultrasonography . Mult Scler vol. 15 , ( 7 ) 795 - 801 .

Idris AI, Sophocleous A, Landao-Bassonga E, Merkouris M, Milligan GI, Baker D, van't Hof RJ, Ralston SH ( 2009 ) . Cannabinoid receptor type 1 protects against age-related bone loss by regulating osteoblast and adipocyte differentiation of bone marrow stromal cells . BONE . vol. 44 , S222 - S222 .

Hooper C, Pinteaux-Jones F, Fry VA, Sevastou IG, BAKER D, Heales SJ, Pocock JM ( 2009 ) . Differential effects of albumin on microglia and macrophages; implications for neurodegeneration following blood-brain barrier damage . J Neurochem vol. 109 , ( 3 ) 694 - 705 .

Amor S, Baker D ( 2009 ) . Experimental autoimmune encephalomyelitis . The Biology of Multiple Sclerosis ,

Gu H, Yi Q, Bray ST, Riddle DS, Baker D, Shiau AK ( 2008 ) . A phage display system for studying the sequence determinants of protein folding . Protein Science vol. 4 , ( 6 ) 1108 - 1117 .

Rigby A, Baker D, Chernajovsky Y ( 2008 ) . Targeting EPO to the CNS; development of a novel therapeutic strategy . IMMUNOLOGY . vol. 125 , 134 - 135 .

Mustafa I, Baker DJ ( 2008 ) . Ventilator Care in the Developing World . Mechanical Ventilation: Clinical Applications and Pathophysiology ,

Baker DJ, Schaefer M, Kennel CF, Gibbons JH, Groat CG, Kennedy D, Rejeski D ( 2008 ) . Response . Science vol. 322 , ( 5903 ) 855 - 856 .

Hampton DW, Anderson J, Pryce G, Irvine KA, Giovannoni G, Fawcett JW, Compston A, Franklin RJM et al. ( 2008 ) . An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss . J NEUROIMMUNOL vol. 201 , 200 - 211 .

Jackson S, Al-Izik S, Pryce G, Giovannoni G, Baker D ( 2008 ) . Fingolimod reduces axonal loss in relapsing secondary progressive experimental autoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 14 , S80 - S81 .

Parkes H, Shorter S, So PW, Baker D, Pryce G, Giovannoni G, Schmierer K ( 2008 ) . High resolution 1H nuclear magnetic resonance spectroscopic-based metabolomic urine analysis of experimental autoimmune encephalitis, a model disease of multiple sclerosis . MULTIPLE SCLEROSIS . vol. 14 , S86 - S87 .

Baker DJ, Wilson WS ( 2008 ) . The Oceanography Society: Its Importance Then and Now . Oceanography vol. 21 , ( 3 ) 22 - 25 .

Al-Izki S, Pryce G, Jackson S, Giovannoni G, Baker D ( 2008 ) . Neuroprotective effects of omega-3 fatty acids in a mouse model of multiple sclerosis . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 173 - 173 .

Rigby A, Chernajovsky Y, Baker D ( 2008 ) . Targeting EPO to the CNS; Development of a novel therapeutic strategy . JOURNAL OF NEUROIMMUNOLOGY . vol. 197 , 171 - 171 .

Schaefer M, Baker DJ, Gibbons JH, Groat CG, Kennedy D, Kennel CF, Rejeski D ( 2008 ) . An Earth Systems Science Agency . Science vol. 321 , ( 5885 ) 44 - 45 .

Anderson JM, Hampton DW, Patani R, Pryce G, Crowther RA, Reynolds R, Franklin RJM, Giovannoni G et al. ( 2008 ) . Abnormally phosphorylated tau is associated with neuronal and axonal loss in experimental autoimmune encephalomyelitis and multiple sclerosis . BRAIN vol. 131 , 1736 - 1748 .

Pinteaux-Jones F, Sevastou IG, Fry VAH, Heales S, Baker D, Pocock JM ( 2008 ) . Myelin-induced microglial neurotoxicity can be controlled by microglial metabotropic glutamate receptors . J NEUROCHEM vol. 106 , ( 1 ) 442 - 454 .

BAKER D, O'NEILL JK, DAVISON AN, TURK JL ( 2008 ) . Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone . Clinical & Experimental Immunology vol. 90 , ( 1 ) 124 - 128 .

Betik AC, Baker DJ, Krause DJ, McConkey MJ, Hepple RT ( 2008 ) . Exercise training in late middle‐aged male Fischer 344 × Brown Norway F1‐hybrid rats improves skeletal muscle aerobic function . Quarterly Journal of Experimental Physiology and Cognate Medical Sciences vol. 93 , ( 7 ) 863 - 871 .

East E, Gverić D, Baker D, Pryce G, Lijnen HR, Cuzner ML ( 2008 ) . Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis during neuroinflammation . Neuropathol Appl Neurobiol vol. 34 , ( 2 ) 216 - 230 .

Croxford JL, Pryce G, Jackson SJ, Ledent C, Giovannoni G, Pertwee RG, Yamamura T, Baker D ( 2008 ) . Cannabinoid-mediated neuroprotection, not immuno suppression, may be more relevant to multiple sclerosis . J NEUROIMMUNOL vol. 193 , ( 1-2 ) 120 - 129 .

Pryce G, Jackson SJ, Baker D ( 2008 ) . Cannabinoids for the Control of multiple Sclerosis . Cannabinoids and the Brain , Springer Nature

Baker D, Pryce G ( 2008 ) . The endocannabinoid system and multiple sclerosis . Curr Pharm Des vol. 14 , ( 23 ) 2326 - 2336 .

( 2007 ) . Correction for Barth et al., Toward high-resolution prediction and design of transmembrane helical protein structures . Proceedings of the National Academy of Sciences of the United States of America vol. 104 , ( 51 ) 20635 - 20635 .

Baker D, Jackson SJ, Pryce G ( 2007 ) . Cannabinoid control of neuroinflammation related to multiple sclerosis . BRIT J PHARMACOL vol. 152 , ( 5 ) 649 - 654 .

Hoi PM, Visintin C, Okuyama M, Gardiner SM, Kaup SS, Bennett T, Baker D, Selwood DL et al. ( 2007 ) . Vascular pharmacology of a novel cannabinoid-like compound, 3-(5-dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methyl-ethyl) benzamide (VSN16) in the rat . BRIT J PHARMACOL vol. 152 , ( 5 ) 751 - 764 .

Pocock JM, Pinteaux-Jones F, Fry VA, Baker D, Heales SJ ( 2007 ) . Metabotropic glutamate receptors on microglia: Switching off toxicity . JOURNAL OF NEUROCHEMISTRY . vol. 102 , 239 - 239 .

Baker DJ ( 2007 ) . The Management of Casualties Following Toxic Agent Release: The Approach Adopted in France . Chemical Warfare Agents , Wiley

Maresz K, Pryce G, Ponomarev ED, Marsicano G, Croxford JL, Shriver LP, Ledent C, Cheng XD et al. ( 2007 ) . Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells . NAT MED vol. 13 , ( 4 ) 492 - 497 .

Pryce G, Baker D ( 2007 ) . Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors . BRIT J PHARMACOL vol. 150 , ( 4 ) 519 - 525 .

Alverson K, Baker DJ ( 2006 ) . Taking the Pulse of the Oceans . Science vol. 314 , ( 5806 ) 1657 - 1657 .

Baker DJ, Hepple RT ( 2006 ) . Elevated caspase and AIF gene expression correlate with progression of sarcopenia during aging in male F344BN rats . Experimental Gerontology vol. 41 , ( 11 ) 1149 - 1156 .

Baker D, Croxford JL, Pryce G, Jackson SM, Ledent C, Marsicano G, Lutz B, Giovannoni G et al. ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 90 - 91 .

Baker D ( 2006 ) . Protection of axonal damage in experimental antoimmune encephalomyelitis . MULTIPLE SCLEROSIS . vol. 12 , S12 - S13 .

Baker D ( 2006 ) . Role of immunity in neurodegeneration in autoimmune encephalomyelitis . JOURNAL OF NEUROIMMUNOLOGY . vol. 178 , 20 - 20 .

Cabranes A, Pryce G, Baker D, Fernandez-Ruiz J ( 2006 ) . Changes in CB1 receptors in motor-related brain structures of chronic relapsing experimental allergic encephalomyelitis mice . BRAIN RES vol. 1107 , 199 - 205 .

Baker DJ, Betik AC, Krause DJ, Hepple RT ( 2006 ) . No Decline in Skeletal Muscle Oxidative Capacity With Aging in Long-Term Calorically Restricted Rats: Effects Are Independent of Mitochondrial DNA Integrity . The Journals of Gerontology Series A vol. 61 , ( 7 ) 675 - 684 .

Hepple RT, Baker DJ, McConkey M, Murynka T, Norris R ( 2006 ) . Caloric Restriction Protects Mitochondrial Function with Aging in Skeletal and Cardiac Muscles . Rejuvenation Research . vol. 9 , 219 - 222 .

Bio FAB Group, Baker D, Church G, Collins J, Endy D, Jacobson J, Keasling J, Modrich P et al. ( 2006 ) . Engineering Life: Building a FAB for Biology . Scientific American vol. 294 , ( 6 ) 44 - 51 .

Bilsland LG, Dick JRT, Pryce G, Petrosino S, Di Marzo V, Baker D, Greensmith L ( 2006 ) . Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice . FASEB J vol. 20 , ( 7 ) 1003 - + .

Baker DJ, Greenhaff PL, Timmons JA ( 2006 ) . Glycogen phosphorylase inhibition as a therapeutic target: a review of the recent patent literature . Expert Opinion on Therapeutic Patents vol. 16 , ( 4 ) 459 - 466 .

Baker DJ, Krause DJ, Howlett RA, Hepple RT ( 2006 ) . Nitric oxide synthase inhibition reduces O2 cost of force development and spares high‐energy phosphates following contractions in pump‐perfused rat hindlimb muscles . Quarterly Journal of Experimental Physiology and Cognate Medical Sciences vol. 91 , ( 3 ) 581 - 589 .

Baker D, Pryce G, Croxford JL, Yamamura T ( 2006 ) . Cannabinoid-mediated immunosuppression in experimental allergic encephalomyelitits . CURRENT TOPICS IN NEUROIMMUNOLOGY . Editors: Tabira, T, Yamamura, T, Kira, J , 109 - 116 .

Cristino L, De Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V ( 2006 ) . Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain . NEUROSCIENCE vol. 139 , ( 4 ) 1405 - 1415 .

Baker D, Pryce G, Davies WL, Hiley CR ( 2006 ) . In silico patent searching reveals a new cannabinoid receptor . TRENDS PHARMACOL SCI vol. 27 , ( 1 ) 1 - 4 .

Ligresti A, Cascio MG, Pryce G, Kulasegram S, Beletskaya I, De Petrocellis L, Saha B, Mahadevan A et al. ( 2006 ) . New potent and selective inhibitors of anandamide reuptake with antispastic activity in a mouse model of multiple sclerosis . BRIT J PHARMACOL vol. 147 , ( 1 ) 83 - 91 .

Walker RC, Raman S, Baker D ( 2006 ) . Poster reception---High resolution, high throughput protein structure prediction using IBM Blue Gene supercomputers . Conference: Proceedings of the 2006 ACM/IEEE conference on Supercomputing - SC '06165 - es .

de Lago E, Fernandez-Ruiz J, Ortega-Gutierrez S, Cabranes A, Pryce G, Baker D, Lopez-Rodriguez M, Ramos JA ( 2006 ) . UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders . EUR NEUROPSYCHOPHARM vol. 16 , ( 1 ) 7 - 18 .

Preece NE, Amor S, Baker D, Gadian DG, O'Neill JK, Urenjak J ( 2005 ) . Experimental encephalomyelitis modulates inositol and taurine in the spinal cord of biozzi mice . Magnetic Resonance in Medicine vol. 32 , ( 6 ) 692 - 697 .

Heijmans N, Smith PA, Morris-Downes MM, Pryce G, Baker D, Donaldson AVJ, 't Hart B, Amor S ( 2005 ) . Encephalitogenic and tolerogenic potential of altered peptide ligands of MOG and PLP in Biozzi ABH mice . J NEUROIMMUNOL vol. 167 , ( 1-2 ) 23 - 33 .

Baker DJ, Hepple RT ( 2005 ) . The Versatility of the Pump-Perfused Rat Hindlimb Preparation: Examples Relating to Skeletal Muscle Function and Energy Metabolism . Applied Physiology Nutrition and Metabolism . vol. 30 , 576 - 590 .

Carli P, Baker DJ ( 2005 ) . Managing mass casualties following toxic agent release . International Journal of Intensive Care vol. 12 , ( 3 )

East E, Baker D, Pryce G, Lijnen HR, Cuzner ML, Gverić D ( 2005 ) . A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis . Am J Pathol vol. 167 , ( 2 ) 545 - 554 .

Pryce G, O'Neill JK, Croxford JL, Amor S, Hankey DJ, East E, Giovannoni G, Baker D ( 2005 ) . Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 41 - 52 .

Amor S, Smith PA, 't Hart B, Baker D ( 2005 ) . Biozzi mice: Of mice and human neurological diseases . J NEUROIMMUNOL vol. 165 , ( 1-2 ) 1 - 10 .

Baker DJ ( 2005 ) . The French prehospital emergency medicine system (SAMU): An introduction . CPD Anaesthesia vol. 7 , ( 1 ) 20 - 25 .

Smith PA, Morris-Downes M, Heijmans N, Pryce G, Arter E, O'Neill JK, 't Hart B, Baker D et al. ( 2005 ) . Epitope spread is not critical for the relapse and progression of MOG 8-21 induced EAE in Biozzi ABH mice . J NEUROIMMUNOL vol. 164 , ( 1-2 ) 76 - 84 .

Idris AI, Hof RJV, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors . NAT MED vol. 11 , ( 7 ) 774 - 779 .

Jackson SJ, Diemel LT, Pryce G, Baker D ( 2005 ) . Cannabinoids and neuroprotection in CNS inflammatory disease . JOURNAL OF THE NEUROLOGICAL SCIENCES . vol. 233 , 21 - 25 .

Hepple RT, Baker DJ, Kaczor JJ, Krause DJ ( 2005 ) . Long‐term caloric restriction abrogates the age‐related decline in skeletal muscle aerobic function . The FASEB Journal vol. 19 , ( 10 ) 1320 - 1322 .

Idris AI, Van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2005 ) . Cannabinoid receptor 1 knockout mice have increased bone mass and are protected from ovariectomy-induced bone loss . BONE . vol. 36 , S132 - S132 .

Pryce G, Baker D ( 2005 ) . Emerging properties of cannabinoid medicines in management of multiple sclerosis . TRENDS NEUROSCI vol. 28 , ( 5 ) 272 - 276 .

Visintin C, Aliev AE, Riddall D, Baker D, Okuyama M, Hoi PM, Hiley R, Selwood DL ( 2005 ) . Membrane receptor probes: Solid-phase synthesis of biotin-Asp-PEG-arvanil derivatives . ORG LETT vol. 7 , ( 9 ) 1699 - 1702 .

Baker D ( 2005 ) . The problem of secondary contamination following chemical agent release . Critical Care vol. 9 , ( 4 )

Gegg ME, Harry R, Hankey D, Zambarakji H, Pryce G, Baker D, Adamson P, Calder V et al. ( 2005 ) . Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction . J IMMUNOL vol. 174 , ( 4 ) 2327 - 2335 .

Jackson SJ, Pryce G, Diemel LT, Cuzner ML, Baker D ( 2005 ) . Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation . NEUROSCIENCE vol. 134 , ( 1 ) 261 - 268 .

Constantinescu CS, Baker D ( 2005 ) . Cytokines in Experimental Autoimmune Encephalomyelitis . Experimental Models of Multiple Sclerosis , Springer Nature

Liu CZ, Green SM, Watkins ND, Baker D, McCaskie AW ( 2005 ) . Dynamic creep and mechanical characteristics of SmartSet GHV bone cement . Journal of Materials Science: Materials in Medicine vol. 16 , ( 2 ) 153 - 160 .

Baker D ( 2005 ) . Genetics of Experimental Allergic Encephalomyelitis . Experimental Models of Multiple Sclerosis , Springer Nature

Jackson SJ, Baker D, Cuzner ML, Diemel LT ( 2004 ) . Cannabinoid-mediated neuroprotection following interferon-gamma treatment in a three-dimensional mouse brain aggregate cell culture . EUR J NEUROSCI vol. 20 , ( 9 ) 2267 - 2275 .

Hagen JL, Krause DJ, Baker DJ, Fu MH, Tarnopolsky MA, Hepple RT ( 2004 ) . Skeletal Muscle Aging in F344BN F1-Hybrid Rats: I. Mitochondrial Dysfunction Contributes to the Age-Associated Reduction in VO2max . The Journals of Gerontology Series A vol. 59 , ( 11 ) 1099 - 1110 .

Hepple RT, Hagen JL, Krause DJ, Baker DJ ( 2004 ) . Skeletal Muscle Aging in F344BN F1-Hybrid Rats: II. Improved Contractile Economy in Senescence Helps Compensate for Reduced ATP-Generating Capacity . The Journals of Gerontology Series A vol. 59 , ( 11 ) 1111 - 1119 .

Idris AI, Van't Hof' RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH ( 2004 ) . Regulation of osteoclastic bone resorption and bone mass by the cannabinoid receptor 1 pathway . JOURNAL OF BONE AND MINERAL RESEARCH . vol. 19 , S284 - S284 .

Pryce G, Jackson SM, Hankey DRJ, Giovannoni G, Baker D ( 2004 ) . Cannabinoids are neuroprotective: dissociation of true neuroprotection from protection secondary to immunosuppression . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 78 - 78 .

Heijmans N, Smith P, Pryce D, Baker D, Morris-Downes M, Amor S ( 2004 ) . Non-encephalitogenic single amino acid substitutions of MOG 8-21 and PLP 56-70 suppress relapsing EAE in ABH mice . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 60 - 60 .

Baker D, Pryce G ( 2004 ) . The potential role of the endocannabinoid system in the control of multiple scleorsis . Current Medicinal Chemistry - Central Nervous System Agents vol. 4 , ( 3 ) 195 - 202 .

East E, Baker D, Pryce G, Cuzner ML, Gveric D ( 2004 ) . The role of plasminogen activators in experimental allergic encephalomyelitis: inflammation and axonal pathology . JOURNAL OF NEUROIMMUNOLOGY . vol. 154 , 167 - 167 .

Roques A, Browne M, Taylor A, New A, Baker D ( 2004 ) . Quantitative measurement of the stresses induced during polymerisation of bone cement . Biomaterials vol. 25 , ( 18 ) 4415 - 4424 .

Ellmerich S, Takacs K, Mycko M, Waldner H, Wahid F, Boyton RJ, Smith PA, Amor S et al. ( 2004 ) . Disease-related epitope spread in a humanized T cell receptor transgenic model of multiple sclerosis . EUR J IMMUNOL vol. 34 , ( 7 ) 1839 - 1848 .

de Lago E, Ligresti A, Ortar G, Morera E, Cabranes A, Pryce G, Bifulco M, Baker D et al. ( 2004 ) . In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake . EUR J PHARMACOL vol. 484 , ( 2-3 ) 249 - 257 .

Wilkinson JD, Whalley BJ, Baker D, Pryce G, Constanti A, Gibbons S, Williamson EM ( 2003 ) . Medicinal cannabis: is Delta(9)-tetrahydrocannabinol necessary for all its effects? . J PHARM PHARMACOL vol. 55 , ( 12 ) 1687 - 1694 .

Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM, Ledent C, Petzold A et al. ( 2003 ) . Cannabinoids inhibit neurodegeneration in models of multiple sclerosis . BRAIN vol. 126 , 2191 - 2202 .

Craner MJ, Kataoka Y, Lo AC, Black JA, Baker D, Waxman SG ( 2003 ) . Temporal course of upregulation of Na-v 1.8 in Purkinje neurons parallels the progression of clinical deficit in experimental allergic encephalomyelitis . J NEUROPATH EXP NEUR vol. 62 , ( 9 ) 968 - 975 .

East E, Baker D, Pryce GM, Cuzner ML, Gveric D ( 2003 ) . The role of plasminogen activators in experimental allergic encephalomyelitis . GLIA . 40 - 40 .

Ahmed Z, Baker D, Cuzner ML ( 2003 ) . Interleukin-12 induces mild experimental allergic encephalomyelitis following local central nervous system injury in the Lewis rat . J NEUROIMMUNOL vol. 140 , ( 1-2 ) 109 - 117 .

Giovannoni G, Baker D ( 2003 ) . Inflammatory disorders of the central nervous system . CURR OPIN NEUROL vol. 16 , ( 3 ) 347 - 350 .

Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR ( 2003 ) . An autoimmune diabetes locus (Idd21) on mouse Chromosome 18 . MAMM GENOME vol. 14 , ( 5 ) 335 - 339 .

Baker D, Hankey DJR ( 2003 ) . Gene therapy in autoimmune, demyelinating disease of the central nervous system . GENE THER vol. 10 , ( 10 ) 844 - 853 .

Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P ( 2003 ) . Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis . FASEB J vol. 17 , ( 8 ) 905 - 907 .

Pryce G, Giovannoni G, Baker D ( 2003 ) . Mifepristone or inhibition of 11 beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice . NEUROSCI LETT vol. 341 , ( 2 ) 164 - 166 .

Petzold A, Baker D, Pryce G, Keir G, Thompson EJ, Giovannoni G ( 2003 ) . Quantification of neurodegeneration by measurement of brain-specific proteins . J NEUROIMMUNOL vol. 138 , ( 1-2 ) 45 - 48 .

Baker D, Pryce G, Giovannoni G, Thompson AJ ( 2003 ) . The therapeutic potential of cannabis . LANCET NEUROL vol. 2 , ( 5 ) 291 - 298 .

Baker D, Pryce G ( 2003 ) . The therapeutic potential of cannabis in multiple sclerosis . EXPERT OPIN INV DRUG vol. 12 , ( 4 ) 561 - 567 .

Craner MJ, Lo AC, Black JA, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2003 ) . Annexin II/piII is up-regulated in Purkinje cells in EAE and MS . NEUROREPORT vol. 14 , ( 4 ) 555 - 558 .

Baker D, Adamson P, Greenwood J ( 2003 ) . Potential of statins for the treatment of multiple sclerosis . LANCET NEUROL vol. 2 , ( 1 ) 9 - 10 .

Shirley P ( 2003 ) . Treatment of biological and chemical casualties in the UK . British Journal of Anaesthesia vol. 90 , ( 1 ) 106 - 107 .

Ahmed Z, Doward AI, Pryce G, Taylor DL, Pocock JM, Leonard JP, Baker D, Cuzner ML ( 2002 ) . A role for caspase-1 and-3 in the pathology of experimental allergic encephalomyelitis - Inflammation versus degeneration . AM J PATHOL vol. 161 , ( 5 ) 1577 - 1586 .

Hall RJ, Hollis-Moffat JE, Merriman ME, Bridges RJ, Green RA, Williams G, Baker D, Merriman TR ( 2002 ) . An autoimmune diabetes locus (ldd21) on mouse chromosome 18 . AMERICAN JOURNAL OF HUMAN GENETICS . vol. 71 , 446 - 446 .

Baker DJ ( 2002 ) . Editorial I Management of casualties from terrorist chemical and biological attack: a key role for the anaesthetist . British Journal of Anaesthesia vol. 89 , ( 2 ) 211 - 214 .

Thompson AJ, Baker D ( 2002 ) . Cannabinoids in MS - Potentially useful but not just yet! . NEUROLOGY vol. 58 , ( 9 ) 1323 - 1324 .

Walters CE, Pryce G, Hankey DJR, Sebti SM, Hamilton AD, Baker D, Greenwood J, Adamson P ( 2002 ) . Inhibition of Rho GTPases with protein prenyltransferase inhibitors prevents leukocyte recruitment to the central nervous system and attenuates clinical signs of disease in an animal model of multiple sclerosis . J IMMUNOL vol. 168 , ( 8 ) 4087 - 4094 .

Morris-Downes MM, Smith PA, Rundle JL, Piddlesden SJ, Baker D, Pham-Dinh D, Heijmans N, Amor S ( 2002 ) . Pathological and regulatory effects of anti-myelin antibodies in experimental allergic encephalomyelitis in mice . J NEUROIMMUNOL vol. 125 , ( 1-2 ) 114 - 124 .

Youssef F, Seifalian AM, Jagroop IA, Myint F, Baker D, Mikhailidis DP, Hamilton G ( 2002 ) . The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT)dagger . EUR J VASC ENDOVASC vol. 23 , ( 4 ) 358 - 364 .

Brooks JW, Pryce G, Bisogno T, Jaggar SI, Hankey DJR, Brown P, Bridges D, Ledent C et al. ( 2002 ) . Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors . EUR J PHARMACOL vol. 439 , ( 1-3 ) 83 - 92 .

Morris-Downes MM, McCormack K, Baker D, Sivaprasad D, Natkunarajah J, Amor S ( 2002 ) . Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2 ',3 '-cyclic nucleotide 3 '-phosphodiesterase (CNPase) in ABH and SJL mice . J NEUROIMMUNOL vol. 122 , ( 1-2 ) 20 - 33 .

Gårdelöf B, Tillant D, Baker DJ ( 2001 ) . Mechanical ventilation during transport of critically ill patients . International Journal of Intensive Care vol. 8 , ( 3 ) 178 - 179 .

O'Neill JW, Kim DE, Johnsen K, Baker D, Zhang KYJ ( 2001 ) . Single-Site Mutations Induce 3D Domain Swapping in the B1 Domain of Protein L from Peptostreptococcus magnus . Structure vol. 9 , ( 11 ) 1017 - 1027 .

Hankey DJR, Nickerson JM, Donoso LA, Lightman SL, Baker D ( 2001 ) . Experimental autoimmune uveoretinitis in mice (Biozzi ABH and NOD) expressing the autoimmune-associated H-2A(g7) molecule: identification of a uveitogenic epitope . J NEUROIMMUNOL vol. 118 , ( 2 ) 212 - 222 .

Ahmed Z, Gveric D, Pryce G, Baker D, Leonard JP, Cuzner ML, Diemel LT ( 2001 ) . Myelin/axonal pathology in interleukin-12 induced serial relapses of experimental allergic encephalomyelitis in the Lewis rat . Am J Pathol vol. 158 , ( 6 ) 2127 - 2138 .

Croxford JL, Feldmann M, Chernajovsky Y, Baker D ( 2001 ) . Different therapeutic outcomes in experimental allergic encephalomyelitis dependant upon the mode of delivery of IL-10: A comparison of the effects of protein, adenoviral or retroviral IL-10 delivery into the central nervous system . J IMMUNOL vol. 166 , ( 6 ) 4124 - 4130 .

Reichel MB, Bainbridge J, Baker D, Thrasher AJ, Bhattacharya SS, Ali RR ( 2001 ) . An immune response after intraocular administration of an adenoviral vector containing a beta galactosidase reporter gene slows retinal degeneration in the rd mouse . BRIT J OPHTHALMOL vol. 85 , ( 3 ) 341 - 344 .

Hankey DJR, Lightman SL, Baker D ( 2001 ) . Interphotoreceptor retinoid binding protein peptide-induced uveitis in B10.RIII mice: Characterization of disease parameters and immunomodulation . EXP EYE RES vol. 72 , ( 3 ) 341 - 350 .

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, Khanolkar A, Layward L et al. ( 2001 ) . Endocannabinoids control spasticity in a multiple sclerosis model . FASEB J vol. 15 , ( 2 ) 300 - 302 .

Baker DJ, Paschen HR ( 2001 ) . Emergency management of injury from the release of toxic substances: Medical aspects of the HAZMAT system . Prehospital Trauma Care ,

Generini S, Matucci-Cerinic M, Partsch G, Stancikova M, Pignone A, Konttinen YT, Rovensky J, Baker DJ et al. ( 2001 ) . Evidence for hyaluronan production in the air pouch model in rats . Clinical and Experimental Rheumatology vol. 19 , ( 3 ) 271 - 276 .

Baker DJ ( 2000 ) . Emergency ventilation . vol. 7 , is. 4 , pp. 229 - 232 . Abstract: java.sql.Clob org.hibernate.engine.jdbc.WrappedClob java.io.Serializable ,

Black JA, Dib-Hajj S, Baker D, Newcombe J, Cuzner ML, Waxman SG ( 2000 ) . Sensory neuron-specific sodium channel SNS is abnormally expressed in the brains of mice with experimental allergic encephalomyelitis and humans with multiple sclerosis . Proceedings of the National Academy of Sciences of the United States of America vol. 97 , ( 21 ) 11598 - 11602 .

Chernajovsky Y, Dreja H, Daly G, Annenkov A, Gould D, Adams G, Croxford JL, Baker D et al. ( 2000 ) . Immuno- and genetic therapy in autoimmune diseases . Genes Immun vol. 1 , ( 5 ) 295 - 307 .

Baker D ( 2000 ) . Reply: a sanguine approach to cannabis . Trends Pharmacol Sci vol. 21 , ( 6 )

Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L ( 2000 ) . Cannabinoids control spasticity and tremor in a multiple sclerosis model . Nature vol. 404 , ( 6773 ) 84 - 87 .

Croxford JL, Triantaphyllopoulos KA, Neve RM, Feldmann M, Chernajovsky Y, Baker D ( 2000 ) . Gene therapy for chronic relapsing experimental allergic encephalomyelitis using cells expressing a novel soluble p75 dimeric TNF receptor . J Immunol vol. 164 , ( 5 ) 2776 - 2781 .

Thoua NM, van Noort JM, Baker D, Bose A, van Sechel AC, van Stipdonk MJB, Travers PJ, Amor S ( 2000 ) . Encephalitogenic and immunogenic potential of the stress protein αB-crystallin in Biozzi ABH (H-2A<SUP>g7</SUP>) mice . JOURNAL OF NEUROIMMUNOLOGY vol. 104 , ( 1 ) 47 - 57 .

Tillan D, Baker DJ, Carli P ( 2000 ) . Mechanical ventilation during transport of critically ill patients . International Journal of Intensive Care vol. 7 , ( 1 ) 59 - 60+62+64 .

Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al. ( 1999 ) . Immunotherapy of auto-immune diseases by gene transfer . Biochem Soc Trans vol. 27 , ( 6 ) 869 - 873 .

Carli P, Baker DJ ( 1999 ) . Trauma . vol. 5 , is. 6 , Wolters Kluwer

Brennan FR, O'Neill JK, Allen SJ, Butter C, Nuki G, Baker D ( 1999 ) . CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease . Immunology vol. 98 , ( 3 ) 427 - 435 .

Baker DJ ( 1999 ) . Editorial . Resuscitation vol. 42 , ( 2 ) 101 - 102 .

Chernajovsky Y, Gould D, Annenkov A, Dreja H, Daly G, Rabinovich GA, Croxford L, Baker D et al. ( 1999 ) . IMMUNOTHERAPY OF AUTOIMMUNE DISEASES BY GENE TRANSFER . Biochemical Society Transactions vol. 27 , ( 5 ) a137 - a137 .

Baker DJ ( 1999 ) . Management of respiratory failure in toxic disasters . Resuscitation . vol. 42 , 125 - 131 .

Baker DJ ( 1999 ) . The pre-hospital management of injury following mass toxic release; a comparison of military and civil approaches . Resuscitation . vol. 42 , 155 - 159 .

Croxford JL, O'Neill JK, Ali RR, Browne K, Byrnes AP, Dallman MJ, Wood MJ, Fedlmann M et al. ( 1998 ) . Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis . Eur J Immunol vol. 28 , ( 12 ) 3904 - 3916 .

Croxford JL, Ali R, Byrnes A, Dallman M, Feldmann M, Baker D ( 1998 ) . Adenoviral gene therapy of experimental allergic encephalomyelitis (EAE) with CTLA4-Ig . Journal of Neuroimmunology vol. 90 , ( 1 )

Thoua N-M, van Noort J, van Sechel A, van Stipdonk M, Baker D, Amor S ( 1998 ) . Encephalitogenicity of the stress protein α-Crystallin in biozzi ABH mice . Journal of Neuroimmunology vol. 90 , ( 1 )

Croxford JL, Triantaphyllopolous K, Feldmann M, Chernajovsky Y, Baker D ( 1998 ) . Gene therapy of experimental allergic encephalomyelitis (EAE) with dimeric TNF receptors using cells as biological pumps . Journal of Neuroimmunology vol. 90 , ( 1 )

Cazalaà JB, Baker DJ ( 1998 ) . Design flaw in continuous syringe pumps . Intensive Care Medicine vol. 24 , ( 6 ) 646 - 647 .

Croxford JL, Triantaphyllopoulos K, Podhajcer OL, Feldmann M, Baker D, Chernajovsky Y ( 1998 ) . Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system . J Immunol vol. 160 , ( 10 ) 5181 - 5187 .

Baker D ( 1998 ) . Medical management of HAZMAT victims in civilian practice . Trends in Anaesthesia and Critical Care vol. 9 , ( 2 ) 52 - 57 .

Chernajovsky Y, Annenkov A, Herman C, Triantaphyllopoulos K, Gould D, Dreja H, Moyes SP, Croxford JL et al. ( 1998 ) . Gene therapy for rheumatoid arthritis. Theoretical considerations . Drugs and Aging vol. 12 , ( 1 ) 29 - 41 .

Triantaphyllopoulos KA, Croxford JL, Baker D, Chernajovsky Y ( 1998 ) . Cloning and expression of murine IFNβ and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis . Gene Therapy vol. 5 , ( 2 ) 253 - 263 .

Ali RR, Reichel MB, Byrnes AP, Stephens CJ, Thrasher AJ, Baker D, Hunt DM, Bhattacharya SS ( 1998 ) . Co-injection of adenovirus expressing CTLA4-Ig prolongs adenovirally mediated lacZ reporter gene expression in the mouse retina . GENE THERAPY vol. 5 , ( 11 ) 1561 - 1565 .

Reichel MB, Ali RR, Thrasher AJ, Hunt DM, Bhattacharya SS, Baker D ( 1998 ) . Immune responses limit adenovirally mediated gene expression in the adult mouse eye . Gene Therapy vol. 5 , ( 8 ) 1038 - 1046 .

O'Neill JK, Baker D, Morris MM, Gschmeissner SE, Jenkins HG, Butt AM, Kirvell SL, Amor S ( 1998 ) . Optic neuritis in chronic relapsing experimental allergic encephalomyelitis in Biozzi ABH mice: Demyelination and fast axonal transport changes in disease . JOURNAL OF NEUROIMMUNOLOGY vol. 82 , ( 2 ) 210 - 218 .

Reichet MB, All RR, Baker D, Byrnes AP, D'Esposito F, Kanuga N, Hunt DM, Bhattacharya SS ( 1997 ) . Co-injection of adenovirus expressing CTLA4-IG prolongs adenovirally-mediated lacz reporter gene expression in the mouse retina . Investigative Ophthalmology and Visual Science vol. 38 , ( 4 )

Thoua NM, van Noort JM, Morris MM, Baker D, Travers PJ, Amor S ( 1997 ) . The heat shock protein αB-crystallin induces EAE in Blozzi ABH mice . Immunology Letters vol. 56 ,

Croxford JL, O'Neill JK, Baker D ( 1997 ) . Polygenic control of experimental allergic encephalomyelitis in Biozzi ABH and BALB/c mice . J Neuroimmunol vol. 74 , ( 1-2 ) 205 - 211 .

Morris MM, Dyson H, Baker D, Harbige LS, Fazakerley JK, Amor S ( 1997 ) . Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection . Journal of Neuroimmunology vol. 74 , ( 1-2 ) 185 - 197 .

Amor S, Baker D, Layward L, McCormack K, Van Noort JM ( 1997 ) . Multiple sclerosis: Variants on a theme . Immunology Today vol. 18 , ( 8 ) 368 - 371 .

Bolton C, O’ Neill JK, Allen SJ, Baker D ( 1997 ) . Regulation of Chronic Relapsing Experimental Allergic Encephalomyelitis by Endogenous and Exogenous Glucocorticoids . International Archives of Allergy and Immunology vol. 114 , ( 1 ) 74 - 80 .

Baker DJ ( 1996 ) . Advanced life support for acute toxic injury (TOXALS™) . European Journal of Emergency Medicine vol. 3 , ( 4 ) 256 - 262 .

Amor S, O'Neill JK, Morris MM, Smith RM, Wraith DC, Groome N, Travers PJ, Baker D ( 1996 ) . Encephalitogenic epitopes of myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein for experimental allergic encephalomyelitis induction in Biozzi ABH (H-2A^g7) mice share an amino acid motif . Journal of Immunology vol. 156 , ( 8 ) 3000 - 3008 .

Brennan FR, ONeill JK, Allen SJ, Mikecz K, Glant TT, Nuki G, Baker D ( 1996 ) . Anti-CD44 antibody prevents and ameriolates chronic relapsing experimental allergic encephalomyelitis (CREAE) by inhibition leukocyte migration to the CNS . ARTHRITIS AND RHEUMATISM vol. 39 , ( 9 ) 625 - 625 .

Baker D, Rosenwasser OA, O'Neill JK, Turk JL ( 1995 ) . Genetic analysis of experimental allergic encephalomyelitis in mice . Journal of Immunology vol. 155 , ( 8 ) 4046 - 4051 .

Amor S, Groome N, Linington C, Morris MM, Dornmair K, Gardinier MV, Matthieu JM, Baker D ( 1994 ) . Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice . The Journal of Immunology vol. 153 , ( 10 ) 4349 - 4356 .

Lapa-e-Silva JR, Pretolani M, Bachelet CM, Baker D, Scheper RJ, Vargaftig BB ( 1994 ) . Emergence of T-lymphocytes, eosinophils and dendritic cells in the bronchi of actively sensitized guinea pigs after antigenic challenge . Brazilian Journal of Medical and Biological Research vol. 27 , ( 7 ) 1653 - 1658 .

Baker D, Butler D, Scallon BJ, O'Neill JK, Turk JL, Feldmann M ( 1994 ) . Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor‐immunoglobulin fusion proteins . European Journal of Immunology vol. 24 , ( 9 ) 2040 - 2048 .

Lapa e Silva JR, Bachelet C-M, Pretolani M, Baker D, Scheper RJ, Vargaftig BB ( 1993 ) . Immunopathologic Alterations in the Bronchi of Immunized Guinea Pigs . American Journal of Respiratory Cell and Molecular Biology vol. 9 , ( 1 ) 44 - 53 .

Amor S, Baker D, Groome N, Turk JL ( 1993 ) . Identification of a major encephalitogenic epitope of proteolipid protein (residues 56-70) for the induction of experimental allergic encephalomyelitis in Biozzi AB/H and nonobese diabetic mice . The Journal of Immunology vol. 150 , ( 12 ) 5666 - 5672 .

Fairchild S, Baker D, Turk JL ( 1993 ) . Characterization of experimental allergic encephalomyelitis-susceptible, Biozzi AB/H (H-2dq1) mice which express H-2Anod: analysis of T-cell receptor expression and the detection of a deletion ligand encoded by Mtv-7 . Immunology vol. 78 , ( 2 ) 260 - 265 .

Lapa e Silva J-R, Pretolani M, Bachelet C-M, Baker D, Shepper RJ, Vargaftig BB ( 1993 ) . Immunohistochemical Characterization of T Lymphocytes and Eosinophils in the Bronchial Wall of Actively Sensitized Guinea Pigs . CHEST Journal vol. 103 , ( 2 ) 130s - 132s .

Liu GY, Baker D, Fairchild S, Figueroa F, Quartey-Papafio R, Tone M, Healey D, Cooke A et al. ( 1993 ) . Complete characterization of the expressed immune response genes in Biozzi AB/H mice: structural and functional identity between AB/H and NOD A region molecules . Immunogenetics vol. 37 , ( 4 ) 296 - 300 .

O'Neill JK, Baker D, Davidson AN, Allen SJ, Butter C, Waldmann H, Turk JL ( 1993 ) . Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies . Journal of Neuroimmunology vol. 45 , ( 1-2 ) 1 - 14 .

Preece NE, Baker D, Butter C, Gadian DG, Urenjak J ( 1993 ) . Experimental allergic encephalomyelitis raises betaine levels in the spinal cord of strain 13 guinea-pigs . NMR Biomed vol. 6 , ( 3 ) 194 - 200 .

Allen SJ, Baker D, O’Neill JK, Davison AN, Turk JL ( 1993 ) . Isolation and characterization of cells infiltrating the spinal cord during the course of chronic relapsing experimental allergic encephalomyelitis in the biozzi ab/h mouse . Cellular Immunology vol. 146 , ( 2 ) 335 - 350 .

O'Neill JK, Baker D, Turk JL ( 1992 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse . Journal of Neuroimmunology vol. 41 , ( 2 ) 177 - 187 .

O'Neill JK, Baker D, Davison AN, Maggon KK, Jaffee BD, Turk JL ( 1992 ) . Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium . Journal of Neuroimmunology vol. 38 , ( 1-2 ) 53 - 62 .

Baker D, Davison AN ( 1991 ) . Mechanisms of immune-mediated demyelinating disease of the central nervous system . Neurochemical Research vol. 16 , ( 9 ) 1067 - 1072 .

Butter C, O'Neill JK, Baker D, Gschmeissner SE, Turk JL ( 1991 ) . An immunoelectron microscopical study of the expression of class II major histocompatibility complex during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neuroimmunol vol. 33 , ( 1 ) 37 - 42 .

Butter C, Baker D, O'Neill JK, Turk JL ( 1991 ) . Mononuclear cell trafficking and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice . J Neurol Sci vol. 104 , ( 1 ) 9 - 12 .

Baker D, O'Neill JK, Turk JL ( 1991 ) . Cytokines in the central nervous system of mice during chronic relapsing experimental allergic encephalomyelitis . Cellular Immunology vol. 134 , ( 2 ) 505 - 510 .

O'Neill JK, Butter C, Baker D, Gschmeissner SE, Kraal G, Butcher EC, Turk JL ( 1991 ) . Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse . Immunology vol. 72 , ( 4 ) 520 - 525 .

Baker D, Kimber I, Ahmed K, Turk JL ( 1991 ) . Antigen-specific and non-specific depression of proliferative responses induced during contact sensitivity in mice . International Journal of Experimental Pathology vol. 72 , ( 1 ) 55 - 65 .

Baker D, O'Neill JK, Amor S, Khamashta MA, Turk JL ( 1991 ) . Inhibition of chronic relapsing experimental allergic encephalomyelitis in the mouse by the alkyl-lysophospholipid ET-18-OCH<inf>3</inf> . International Journal of Immunopharmacology vol. 13 , ( 4 ) 385 - 392 .

Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL ( 1991 ) . Suppression of demyelination by mitoxantrone . Int J Immunopharmacol vol. 13 , ( 7 ) 923 - 930 .

Wilcox CE, Ward AM, Evans A, Baker D, Rothlein R, Turk JL ( 1990 ) . Endothelial cell expression of the intercellular adhesion molecule-1 (ICAM-1) in the central nervous system of guinea pigs during acute and chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 30 , ( 1 ) 43 - 51 .

Baker D, O'Neill JK, Gschmeissner SE, Wilcox CE, Butter C, Turk JL ( 1990 ) . Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice . Journal of Neuroimmunology vol. 28 , ( 3 ) 261 - 270 .

Schäfer H, Baker D, Thiele B, Burger R ( 1990 ) . Structure, cellular distribution, and functional characteristics of the guinea pig leucocyte common antigen . Cellular Immunology vol. 128 , ( 2 ) 370 - 384 .

Kimber I, Cumberbatch M, Bentley AN, Baker D ( 1990 ) . Requirements for antigenic competition in contact sensitivity . Journal of Clinical and Laboratory Immunology vol. 32 , ( 2 ) 67 - 72 .

Butter C, Healey DG, Baker D, Turk JL ( 1989 ) . A quantitative immunocytochemical study of the infiltrating lymphocytes in the spinal cord of guinea pigs with chronic relapsing experimental allergic encephalomyelitis . J Neuroimmunol vol. 25 , ( 2-3 ) 169 - 176 .

Wilcox CE, Healey DG, Baker D, Willoughby DA, Turk JL ( 1989 ) . Presentation of myelin basic protein by normal guinea-pig brain endothelial cells and its relevance to experimental allergic encephalomyelitis . Immunology vol. 67 , ( 4 ) 435 - 440 .

Wilcox CE, Baker D, Butter C, Willoughby DA, Turk JL ( 1989 ) . Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis . Cell Immunol vol. 120 , ( 1 ) 82 - 91 .

Kimber I, Shepherd CJ, Mitchell JA, Turk JL, Baker D ( 1989 ) . Regulation of lymphocyte proliferation in contact sensitivity: homeostatic mechanisms and a possible explanation of antigenic competition . Immunology vol. 66 , ( 4 ) 577 - 582 .

Baker D, Kimber I, Turk JL ( 1989 ) . Antigen-specific regulation of T lymphocyte proliferative responses to contact-sensitizing chemicals in the guinea pig . Cellular Immunology vol. 119 , ( 1 ) 153 - 159 .

Kraal G, Shiamatey-Koolma R, Hoffer M, Baker D, Scheper R ( 1988 ) . Histochemical identification of guinea-pig macrophages by monoclonal antibody MR-1 . Immunology vol. 65 , ( 4 ) 523 - 528 .

Baker D, Parker D, Healey DG, Turk JL ( 1987 ) . Induction of sensitization and tolerance in contact sensitivity with haptenated epidermal cells in the guinea-pig . Immunology vol. 62 , ( 4 ) 659 - 664 .

Antoniou AV, Baker D, El-Sady E, Turk JL, Tan BTG, Scheper RJ ( 1987 ) . Identification and quantitation of the expression of T cell surface markers during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig . Journal of Neuroimmunology vol. 14 , ( 3 ) 293 - 303 .

BAKER D, PARKER DD, TURK JL ( 1985 ) . Effect of depletion of epidermal dendritic cells on the induction of contact sensitivity in the guinea‐pig . British Journal of Dermatology vol. 113 , ( 3 ) 285 - 294 .